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Abstract
Development of specific inhibitors targeting the enzyme aromatase represents a highly successful
example of rational drug design in hormone-responsive cancer. Aromatase inhibitors (AI) are approved as
a first line of therapy in both primary and metastatic estrogen-receptor positive (ER+) breast cancer, and
have been shown to be superior to tamoxifen at preventing local and distant recurrence. In spite of the
improved clinical efficacy, approximately 20% of women taking AI relapse within 10 years of diagnosis
and mechanisms of resistance vary widely. Pre-clinical and small clinical studies have found differences
in biochemical efficacy among commonly used third-generation AI that suggest the potential for
incomplete estrogen suppression in a proportion of women on AI. However, the relationship between suboptimal estrogen suppression during initial or adjuvant AI and disease outcomes has never been
systemically explored. Liquid-chromatography / tandem mass spectrometry (LC-MS/MS) and liquid
chromatography - high resolution mass spectrometry (LC-HRMS) assays provide robust, versatile and
highly sensitive platforms for reliable quantification of sex steroids at trace levels present in circulation in
post-menopausal women and in women on AI. In this dissertation, rapid and highly sensitive LC-HRMS
assays were applied in vitro to conduct a comprehensive analysis of biochemical efficacy of thirdgeneration AI in cell models of AI therapy and resistance. These studies demonstrated that among the
third generation AI, letrozole has the greatest efficacy for suppressing estradiol and estrone formation
from testosterone and Δ4-androstendione in vitro. Biological response and metabolism of the circulating
steroid precursor dehydroepiandrosterone (DHEA) and its sulfate conjugate was assessed in in vitro
models of ER+ breast cancer (MCF-7 variant cell lines +/- aromatase). These studies demonstrated
estrogen formation from physiological levels of DHEA and DHEA-S in MCF-7 variants after growth in
steroid-depleted conditions only in the presence of aromatase. An exploratory clinical study was
undertaken for a first look into the variety of estrogen and androgen levels present in serum of women
taking adjuvant AI who go on to relapse. A wide variety of serum estrogen levels were quantified from
women in this cohort, demonstrating incomplete serum estrogen suppression in approximately half of the
women analyzed. The applicability of this work is to shed light on the potential for variable individual
response to AIs and the need for larger clinical studies examining the relationship between sub-optimal
suppression of estrogens in the initial and adjuvant settings and disease outcomes.
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The real voyage of discovery consists not in
seeking new landscapes, but in seeing with new eyes.

Marcel Proust
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ABSTRACT

TRACING ANDROGEN METABOLISM WITH INHIBITION OF AROMATASE IN
BREAST CANCER: IN VITRO STUDIES AND CLINICAL CORRELATES

Lisa N. Bottalico
Ian A. Blair, Ph.D.
Development of specific inhibitors targeting the enzyme aromatase represents a highly
successful example of rational drug design in hormone-responsive cancer. Aromatase
inhibitors (AI) are approved as a first line of therapy in both primary and metastatic
estrogen-receptor positive (ER+) breast cancer, and have been shown to be superior to
tamoxifen at preventing local and distant recurrence. In spite of the improved clinical
efficacy, approximately 20% of women taking AI relapse within 10 years of diagnosis
and mechanisms of resistance vary widely. Pre-clinical and small clinical studies have
found differences in biochemical efficacy among commonly used third-generation AI that
suggest the potential for incomplete estrogen suppression in a proportion of women on
AI. However, the relationship between sub-optimal estrogen suppression during initial or
adjuvant AI and disease outcomes has never been systemically explored. Liquidchromatography / tandem mass spectrometry (LC-MS/MS) and liquid chromatography high resolution mass spectrometry (LC-HRMS) assays provide robust, versatile and
highly sensitive platforms for reliable quantification of sex steroids at trace levels present
in circulation in post-menopausal women and in women on AI. In this dissertation, rapid
and highly sensitive LC-HRMS assays were applied in vitro to conduct a comprehensive
v

analysis of biochemical efficacy of third-generation AI in cell models of AI therapy and
resistance. These studies demonstrated that among the third generation AI, letrozole has
the greatest efficacy for suppressing estradiol and estrone formation from testosterone
and ∆4-androstendione in vitro. Biological response and metabolism of the circulating
steroid precursor dehydroepiandrosterone (DHEA) and its sulfate conjugate was assessed
in in vitro models of ER+ breast cancer (MCF-7 variant cell lines +/- aromatase). These
studies demonstrated estrogen formation from physiological levels of DHEA and DHEAS in MCF-7 variants after growth in steroid-depleted conditions only in the presence of
aromatase. An exploratory clinical study was undertaken for a first look into the variety
of estrogen and androgen levels present in serum of women taking adjuvant AI who go
on to relapse. A wide variety of serum estrogen levels were quantified from women in
this cohort, demonstrating incomplete serum estrogen suppression in approximately half
of the women analyzed. The applicability of this work is to shed light on the potential for
variable individual response to AIs and the need for larger clinical studies examining the
relationship between sub-optimal suppression of estrogens in the initial and adjuvant
settings and disease outcomes.
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CHAPTER 1: INTRODUCTION

1-1: A brief history of endocrine therapy in breast cancer
One of the earliest reports of an endocrine-targeted therapy in breast cancer was a
case report published in 1896 describing a pre-menopausal woman with inoperable breast
cancer treated with oophorectomy, which led to regression of her tumor [1, 2]. Through
the years, endocrine treatments in breast cancer included oophorectomy, adrenalectomy
and hypophysectomy, though early uses of these treatments did not distinguish between
breast cancers expressing the estrogen receptor (ER), and there was about a 30% response
rate [3]. The isolation of ER [4, 5], and subsequent ability to measure ER-expression in
patients led to the ability to identify which patients would respond to endocrine-targeted
therapies in breast cancer [6].
The first non-surgical endocrine-targeted therapy in breast cancer was “medical
adrenalectomy” with the drug aminoglutethimide (AG) [7]. AG inhibits adrenal action
through inhibition of P450 side-chain cleavage enzyme and was later found to inhibit
estrogen production in post-menopausal women [8]. The selective estrogen receptor
modulator (SERM) tamoxifen was developed around the same time and became the first
line of therapy in ER+ breast cancer because it had fewer side effects and less toxicity
than AG [9]. In the 1970s, the strategy of depriving tumors of estrogens led to efforts
pioneered by Harry and Angela Brodie to design a specific inhibitor of the enzyme
aromatase, which catalyzes the conversion of 19-carbon androgens to 18-carbon
estrogens, and is the main source of estrogen production in post-menopausal women [10].
1

Their work led to the development of the mechanism-based inactivator 4hydroxyandrostenedione, later named formestane, which became the first selective
inhibitor of aromatase to be approved for clinical use, and was approved as a second-line
of therapy after tamoxifen to treat ER+ breast cancer after menopause [9, 11]. Tamoxifen
remained the first-line of therapy in ER+ early and advanced ER+ breast cancer after
menopause for 20 years until advances in potency and specificity of AI led to thirdgeneration AI compounds taking the place of tamoxifen as the first line of therapy in
early and advanced disease [9].
Endocrinologist Richard Santen has described the enzyme aromatase as “one of
the first molecular targets for rational drug development in the treatment of cancer” [9].
The discovery of aromatase and characterization of its function, followed by efforts
pioneered by the Brodie’s to find specific mechanism-based aromatase inhibitors, and
subsequent advances in specificity and potency of AI have advanced endocrine-therapy
of ER+ breast cancer from surgical to targeted therapy. Figure 1.1 shows structures of
some of the 1st, 2nd and 3rd generation AIs [12].

1-2: Estrogen action in ER+ breast cancer
Endocrine therapies in breast cancer are therapies which disrupt estrogen-receptor
signaling or function. Modern endocrine-targets in breast cancer include drugs that inhibit
the production or action of estrogens [12, 13]. Aromatase inhibitors inhibit conversion of
adrenal androgens to estrogens in circulation and in target tissues of post-menopausal
women [14]. Other therapies disrupt estrogen signaling at the site of the estrogen
2
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Figure 1.1: Structures of ∆4-androstenedione and a sample of first, second and third-generation
aromatase inhibitors.
A: ∆4-androstenedione, the natural substrate of aromatase. B and C: ∆4-androstenedione analogs and
mechanism-based inhibitors of aromatase. D-F: Non-steroidal first and third generation aromatase
inhibitors. Published in Nat Rev Cancer. 2003 Nov;3(11):821-31.
3

receptor, such as the selective estrogen receptor modulator (SERM) tamoxifen which
disrupts ER signaling in a tissue-specific manner, and the selective estrogen receptor
degrader (SERD) fulvestrant which targets ER for degradation [13].
Approximately 70% of all breast tumors express ER [15], and the receptor has
two isoforms ERα and ERβ which can stimulate differential gene expression and cellular
responses [16]. The proliferative action of estrogen proceeds largely through ERα and in
this text, ERα will be subsequently referred to as ER, unless the beta-isoform of the
receptor is specified. 17β-estradiol can stimulate genomic effects by binding ER in the
cytoplasm and subsequent translocation of the ligand-bound receptor to the nucleus, as
well as “non-genomic” cellular effects which occur upon binding ER present in the
plasma membrane and direct stimulation of cell signaling events [17-19].
The carcinogenic effects of 17β-estradiol and its metabolites occur through
stimulation of proliferation through ER as well as direct DNA damage [20, 21].
Metabolites of estradiol, particularly the highly reactive ortho-quinones derived from
catechol metabolites can directly bind DNA, leading to formation of depurinating adducts
and can also undergo catechol-quinone redox cycling which results in generation of
reactive oxygen species that can cause both direct DNA damage and oxidative stress [2225].

4

1-3: From the adrenal gland to the breast: local estrogen production in breast tissue

In the 1970s, sentinel discoveries were made demonstrating that 19-carbon (C-19)
adrenal androgens could be converted to estrogens systemically and by breast tumor
tissue from post-menopausal women [26, 27]. Subsequent work demonstrated the
importance of the enzyme aromatase in catalyzing this conversion and determining breast
tissue estrogen concentrations in the normal breast and in breast cancer. William Miller
and John O’Neill demonstrated that aromatase activity in breast tissue sections from
women after mastectomy differed based on proximity to tumor site [28, 29] and work by
Angela Brodie confirmed expression of aromatase in breast tissue using
immunocytochemistry [30]. Measurement of estrone, estradiol and estrone-sulfate
conjugates in serum vs. tissue of post-menopausal women revealed significantly higher
concentrations of these estrogens in tissue, which were found to be further elevated in
breast cancer [31, 32]. These studies and others formed the rationale for targeting
aromatase function in breast cancer.
Adipose, stromal, epithelial cells and macrophages have all been demonstrated to
have aromatase activity and contribute to local formation of estrogen in the breast [3336]. Estrogen formation and action therefore proceeds through autocrine, intracrine,
paracrine and juxtacrine mechanisms in breast tissue [9]. The importance of steroidsulfatase expression has also been explored in breast cancer, as it catalyzes the
conversion of estrogen-sulfates present in circulation and in tissue to unconjugated

5

Figure 1.2: The formation of estrogens in the tissue postmenopausal women from
circulating C-19 androgens and sulfate precursors.

6

estrogens capable of binding ER [37-39]. Expression of other steroid hormone
metabolizing enzymes such as aldo-keto reductase 1C3 (AKR1C3) and various isoforms
of 17β-hydroxysteroid dehydrogenase (17β-HSD) are important in determining the
capacity for local metabolism of adrenal androgens to estrogens in the breast as well as
determining the rate of conversion of the less potent ER ligand estrone to the more potent
ER ligand estradiol [40-42]. Importantly aromatase, steroid sulfatase, AKR1C3 and
isoforms of 17β-HSD have all been found to be overexpressed in breast cancer [37, 41,
43, 44], with some indication of further modulation in the presence of AI [45]. Therefore,
while aromatase is the first specific enzyme to be targeted for the purpose of suppressing
local estrogen formation, in the dynamic environment breast and/or tumor tissue,
expression levels of a suite of androgen and estrogen metabolizing enzymes can be
modulated to influence the capacity for local estrogen production from adrenal or
conjugated precursors [46, 47]. Figure 1.2 shows a metabolism schema of formation of
estrogens in breast tissue from C-19 and conjugated precursors.

1-4: Targeting aromatase in ER+ breast cancer after menopause
After the development and clinical approval of formestane demonstrated the
ability to specifically target aromatase activity in ER+ breast cancer rather than general
ovarian or adrenal function, pharmaceutical companies lent their efforts towards largescale screening studies aimed at identifying compounds that would have greater
specificity and potency for inhibiting aromatase than 1st and 2nd generation AIs [9]. This
led to the discovery of letrozole, anastrozole and exemestane, which became known as
7

third-generation AI due to their significantly greater specificity and potency for binding
and inhibiting aromatase [14, 48]. Figure 1.3 shows comparative biochemical efficacy of
fadrozole and formestane, two 2nd generation compounds compared with third generation
compounds [9]. Third-generation AI were demonstrated to have superior clinical efficacy
compared with second-generation compounds [14], and two major Phase III clinical
trials: the Arimidex or Tamoxifen Alone or in Combination (ATAC) and The Breast
International Group (BIG) 1-98 study (BIG 1-98) compared the clinical efficacy of
anastrozole vs. tamoxifen (ATAC) and letrozole vs. tamoxifen (BIG 1-98) in early breast
cancer [49, 50]. Positive results of these studies led to the approval of both AIs in early
breast cancer, and the 10-year follow-up studies later led to the approval of thirdgeneration AI as a first line of therapy in advanced breast cancer as well [51, 52].

1-5: What went wrong? Mechanisms of resistance to AI therapy in breast cancer
While AIs have demonstrated significantly greater clinical efficacy in both early
and later stages of ER+ breast cancer compared with tamoxifen, up to 20% of women
will relapse within 10 years [51, 53]. Mechanisms of resistance can vary widely among
individuals and resistance can be either intrinsic or acquired. It is important to note that
acquired resistance to AI is not the same as ER-negative breast cancer cell growth, as
discussed in the following review [54].
In vitro models of AI-responsive and AI-resistant breast cancer have been utilized
to understand cellular responses to estrogen deprivation [55-57]. Changes found include
activation of growth factor signaling pathways, such as EGF-R and HER2 that can
8

Figure 1.3: Biochemical efficacy of aromatase inhibitors assessed by isotopic
kinetic assay. Arrows indicate dosages used in clinical practice for thirdgeneration AI. FAD= fadrozole, FOR= formestane, ANA= anastrozole, EXE=
exemestane, LET= letrozole. Published in Endocr Rev. 2009 Jun;30(4):343-75 and
in H. Kronenberg, S. Melmed, K. Polonsky, P. R. Larsen 2008 Williams Textbook
of Endocrinology, 11th Edition, Philadelphia: Saunders.
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stimulate proliferation through cross-talk with ER, phosphorylation of the estrogen
receptor and subsequent ligand-independent activation of ER [58-64]. The changing
nature of susceptibility to growth induction by 17β-estradiol (E2) in the transition to AI
and endocrine resistance has been described as tumor cells first responding to complete
estrogen deprivation by developing hypersensitivity to E2, followed by development of
complete estrogen independence [54]. An interesting finding was reported of treatment
with E2 treatment re-sensitizing AI-resistant tumors in nude mice to growth inhibition by
letrozole [65], which reflects the rapid adaptation of cells and tumors to their
environment and to the availability of ER ligands. Additionally, targeting Her2, a
receptor that can be co-expressed with ER has led to improved outcomes in some patients
resistant to AI [66].
An important but less discussed resistance mechanism involves the breast tumor’s
ability to modulate its local steroid hormone metabolism to increase formation of
estrogens potentially through pathways other than aromatization. The over-expression of
important steroid hormone metabolizing enzymes in breast cancer such as steroidsulfatase, 17β-HSDs and AKR1C3 demonstrates the ability of breast tissue to modulate
local metabolism as needed to promote a more estrogenic state. Investigations into
enzyme expression changes that occur as a result of AI therapy are limited but important
areas for further investigation [45, 46]. In a recent report, CYP19A1 (aromatase) gene
amplification and increased aromatase activity was found to be an early mechanisms of
AI resistance in ERα metastatic breast cancer [67]

10

A potential resistance mechanism that is least discussed is the potential for
incomplete estrogen suppression to drive therapeutic response. Studies which have
detailed growth factor signaling mechanisms driving AI-resistant growth have done so in
models of complete estrogen deprivation. However, the proportion of women who don’t
respond to early or adjuvant AI due to incomplete estrogen suppression is not known.
Some studies suggest that there is a wide variability in response to AI which could lead to
a lack of estrogen suppression in some women taking these drugs [68]. Also, mechanisms
of resistant tumor growth that develop in the completely absence of estradiol are likely to
be different than mechanisms of resistant tumor growth that develop after long-term
growth in partial but not complete estrogen suppression [69]. If hypersensitivity is a
passing growth phase on the progression towards complete estrogen independence, what
properties develop in tumors that progress in a permanent state of partial but not complete
estrogen suppression?
It has been stated that the wide variety of resistance mechanisms seen in cell
models of acquired resistance to AI is reflective of the wide variability of resistance
mechanisms seen in women taking these drugs [54]. Investigating variability not only in
cell signaling mechanisms but also in degree of estrogen suppression among women
taking AI is a worthwhile endeavor. A model of the prevailing view on the progression
towards estrogen-independence in breast cancer is shown in Figure 1.4 (published in
[70].
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Figure 1.4: Prevailing view on the progression towards hormone independence in breast
cancer. Published in JSBMB 2010 Feb 28;118(4-5):277-82.

1-6: Monitoring AI therapy and risk for relapse in breast cancer
There is a critical need for development of assays to reliably monitor estrogens
and androgens at low levels present in circulation of post-menopausal women to better
understand associations of circulating sex steroids with breast cancer risk and to assess
AI therapeutic response [71, 72]. Immune-based methods (radioimmunoassay and
enzyme-linked immunosorbent assay (ELISA) have most frequently been utilized for
quantification of serum estrogens and androgens, but such assays lack the specificity to
distinguish between steroid metabolites, many of which have similar structures [73].
Such assays are particularly problematic for measuring estradiol [74-76].
Early assessment of AI response in post-menopausal women was conducted using
isotopic tracer techniques for the third-generation AI individually, and the range of
inhibition of whole-body aromatization ranged from 97 – 99% with letrozole
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demonstrating the highest degree of inhibition of whole-body aromatization [77-79].
Aromatization was inhibited by 98.4 - 99.1% with letrozole, compared with 96.7 – 98.1%
with anastrozole and 97.9% with exemestane [77-79]. A study designed to directly
compare degree of inhibition of total body aromatization between letrozole and
anastrozole also demonstrated a greater biochemical efficacy of letrozole [80]. These
studies have provided important understanding of degree of inhibition of total body
aromatase in women on AI, but studies are limited to small numbers of patients. Clinical
studies to assess the variability of estrogen suppression in larger populations of women
treated with AIs and using accurate methods have not been conducted.
The dependence on immune-based methods for quantification of serum estrogens
and androgens has led to uncertainty regarding the true baseline variability of estrogen
and androgen levels in post-menopausal women [73, 81]. Gas-chromatography (GC) or
liquid-chromatography (LC) coupled with mass spectrometry can provide the sensitivity
and specificity needed to assess biological variability of serum steroid hormones in
healthy post-menopausal women, investigate the relationship between circulating
estrogens and androgens and breast cancer risk and to investigate variability in extent of
estrogen suppression among women treated with AIs [82, 83].
With a focus in the field on cell signaling changes that can allow breast tumors to
adapt to growth in the absence of estradiol, there has been an informal assumption that
complete estrogen suppression is both achieved and sustained in a majority of women on
AI, and further, that differences in AI potency don’t matter if the progression in breast
cancer is towards hormone-independent growth [84]. Without methods capable of
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accurately quantifying low and trace estrogen levels that are present in women on AI as
well as an assessment of the variability of response in larger populations of women, it
cannot be assumed that complete estrogen suppression is the norm among women treated
with AI. Application of reliable MS-based techniques will allow for studies to assess the
relationship between suboptimal estrogen suppression and disease outcomes, both at the
onset of AI therapy and in the adjuvant setting.

1-7: DHEA and DHEA-S action in breast cancer
The adrenal steroid dehydroepiandrosterone (DHEA) and its sulfate conjugate are
present in circulation of both women and men at high concentrations and are precursors
for the peripheral formation of estrogens and androgens in target tissues [85]. Despite the
high concentration present in circulation and tissue-specific metabolism, the potential
role of DHEA or DHEA-S in breast cancer has not been well-clarified. Limited
epidemiological evidence suggests that high circulating DHEA or DHEA-S levels are
associated with breast cancer risk and potentially with resistance to endocrine-targeted
therapies [86-89]. However, studies conducted in vitro and in rodent models have yielded
conflicting results revealing the potential for both proliferative and anti-proliferative
effects of DHEA in breast cancer [90-94]. Additional discrepancies exist regarding
whether DHEA exerts its biological effect through the estrogen receptor (ER), through
the androgen receptor (AR), or independent of ER and AR [95-97]. Finally, studies
assessing metabolism of DHEA by breast cancer cells in culture have demonstrated
formation of both estrogens [98-100] and androgens [92, 101] from DHEA or DHEA-S
14

and authors have argued the importance of formation of both. As discussed in the
previous section, some of these discrepancies may be explained by differences in
methods used to quantify estrogen and androgen formation, i.e. immunoassay vs. mass
spectrometry-based methods. Better understanding of DHEA and DHEA-S metabolism
and action in breast cancer can be gained through application of MS-based methods that
have the sensitivity and specificity to reliably detect formation of androgens and
estrogens from DHEA and DHEA-S precursors in in vitro models of hormone-sensitive
breast cancer as well as in vivo.

1-8: Overview of chapters
Chapter 2: In Chapter 2, I will discuss the association of serum estrogens and androgens
with breast cancer risk, and limitations of immune-based methods which have frequently
been employed for quantification of steroid hormones. Methodological challenges and
use of methods without specificity to distinguish between steroid hormone metabolites
with similar structure has led to uncertainty about the true biological range of estrogens
and androgens in post-menopausal women. A review of estrogen and androgen levels
reported in the literature in healthy post-menopausal women after quantification by
liquid-chromatography selected-reaction monitoring mass spectrometry (LC-SRM/MS)
will be presented.
Chapter 3: In Chapter 3, I will discuss application of liquid-chromatography / high
resolution mass spectrometry assays for quantification of estrogens and androgens from
human biological samples, including development of an assay for rapid and highly
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sensitive quantification of estrone and estradiol from biological matrices. These assays
have been employed for quantification of estrogens and androgens in women on adjuvant
AI (Chapter 6) and for studying androgen metabolism in cell models of AI therapy and
resistance (Chapters 4 and 5). The experiments detailed in Chapter 3 were early
experiments to assess baseline characteristics of the cell models of AI-responsive and
resistant breast cancer used in later experiments, and conditions for quantifying low-level
estrogen formation from androgen precursors both intracellularly and extracellularly.
Chapter 4: Experiments conducted to quantify estrogen formation from androgen
precursors in cell models of AI-responsive vs. resistant breast cancer are presented in
Chapter 4. Comparative potency to inhibit estrogen formation among the third-generation
AI was explored in vitro.
Chapter 5: Growth response and metabolism of DHEA and DHEA-S at physiological
concentrations was assessed in MCF-7 and variant cell lines (+/- aromatase and after
long-term estrogen deprivation). Experiments exploring differential metabolism of
DHEA and DHEA-S in the presence or absence of aromatase are detailed in Chapter 5.
Chapter 6: A small clinical study (n=23) assessing serum estrogen and androgen levels
in women on adjuvant AI who progressed to metastatic breast cancer is presented in
Chapter 6.
Chapter 7: In Chapter 7, I will discuss overall conclusions and future directions of both
in vitro and clinical studies.
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CHAPTER 2: Analysis of estrogens and androgens in post-menopausal serum and
plasma by liquid chromatography – mass spectrometry

Published as: Wang Q, Bottalico L, Mesaros C, Blair IA., Analysis of estrogens and
androgens in postmenopausal serum and plasma by liquid chromatography-mass
spectrometry, Steroids, 2015 Jul; 99(Pt A): 76-83.

2-1: Abstract

Liquid chromatography-selected reaction monitoring/mass spectrometry-based
methodology has evolved to the point where accurate analyses of trace levels of estrogens
and androgens in postmenopausal serum and plasma can be accomplished with high
precision and accuracy. A suite of derivatization procedures has been developed, which
together with modern mass spectrometry instrumentation provide investigators with
robust and sensitive methodology. Pre-ionized derivatives are proving to be useful as
they are not subject to suppression of the electrospray signal. Postmenopausal women
with elevated plasma or serum estrogens are thought to be at increased risk for breast and
endometrial cancer. Therefore, significant advances in risk assessment should be
possible now that reliable methodology is available. It is also possible to conduct
analyses of multiple estrogens in plasma or serum. Laboratories that are currently
employing liquid chromatography/mass spectrometry methodology can now readily
implement this strategy. This will help conserve important plasma and serum samples
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available in Biobanks, as it will be possible to conduct high sensitivity analyses using low
initial sample volumes. Reported levels of both conjugated and non-conjugated estrogen
metabolites are close to the limits of sensitivity of many assays to date, urging caution in
the interpretation of these low values. The analysis of serum androgen precursors in
postmenopausal women has not been conducted routinely in the past using liquid
chromatography/mass spectrometry methodology. Integration of serum androgen levels
into the panel of metabolites analyzed could provide additional information for assessing
cancer risk and should be included in the future.
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2.2: Introduction
There is a compelling need for reliable methodology capable of quantifying
estrogens in the serum of postmenopausal women because increased levels appear to be
associated with increased breast cancer risk [102, 103]. Estrogen carcinogenesis arises
through a dual mechanism in which estradiol can act either as a hormone to stimulate
aberrant cell proliferation or as the precursor to the formation of genotoxic catechol
metabolites [104]. Estrogen levels in the breast tissues of postmenopausal women are
dependent upon the availability of circulating C-19 androgen precursors, which are
converted to estrogens in the tissue (See Figure 1.2). Estrogens can then be released into
the circulation, providing biomarkers of tissue estrogen biosynthesis if it is assumed that
the circulating levels are reflective of tissue concentrations. This assumption has been
questioned because tissue levels of estrogens are significantly higher than the
corresponding circulating levels and breast tissue-specific metabolism is known to occur.
A pharmacokinetic model has been proposed in which there is rapid equilibrium between
tissue and plasma estrogens that may might explain this conundrum [105].
The analysis of circulating androgens concentrations can provide insight into
availability of relevant androgen precursors, such as androstenedione and testosterone,
which can be taken up into tissue (Figure 1.2). In postmenopausal women, such an
analysis could provide useful additional biomarkers of breast cancer risk. Circulating
sulfate conjugates have the potential to provide a source of estrogens in breast tissue
through the action of sulfatases, which would release the corresponding non-conjugated
steroids [106]. This is particularly relevant to circulating estrone-3-sulfate (a precursor to
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estrone) and dehydroepiandrosterone (DHEA) sulfate, a precursor to DHEA, which is a
substrate for 3β-hydroxysteroid dehydrogenase (HSD)-mediated conversion to
androstenedione. The androstenedione can in turn be converted to estrone by aromatase
(Figure 1.2). However, there is little evidence that the conversion of circulating sulfate
conjugates to tissue androgens and estrogens actually takes place [105]. Furthermore, the
polar nature of the sulfate conjugates suggests that they are not good substrates for
passive diffusion from the plasma into breast tissue. However, the ability of multiple
drug transporter (MRP)-1 (ABCC1) to transport estrone-3-sulfate [107] and MRP-1 and
MRP-4 (ABCC4) to transport DHEA sulfate [108] does provide an alternative
mechanism for the conjugated steroids to be taken up by breast tissue. Therefore, the
analysis of circulating estrone-3-sulfate and DHEA sulfate in postmenopausal women
could also be informative.
Aromatase inhibitors have significantly improved the recurrence-free and overall
survival rates in breast cancer patients [109]. Unfortunately, only incremental progress
has been made over the last decade in preventing breast cancer among postmenopausal
women. There is a compelling need to improve this situation in view of the aging world
population and the role of aging as an important determinant of breast cancer risk [110,
111]. It is clear that implementation of breast cancer prevention programs will require
selection of women with high breast cancer risk in order to maximize the benefit/risk
ratio [112, 113]. It is anticipated that significant advances in risk assessment will be
possible if reliable methodology is available to quantify estrogens and androgens in the
plasma or serum of postmenopausal women [110]. These measurements can be coupled
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with other risk factors such as mammographic density [114], bone density [115], body
mass index (BMI) [116], and single-nucleotide polymorphisms associated with breast
cancer [117] to provide an improved model of breast cancer risk [112]. The present
review will focus on the analysis of non-conjugated and conjugated estrogens and
androgens using highly specific and sensitive stable isotope dilution liquid
chromatography/mass spectrometry methodology that can be used to assess breast cancer
risk.

2-3: Non-conjugated estrogens
Non-conjugated estradiol and its downstream non-conjugated metabolites are
present in plasma and serum in the free form (not bound to steroid binding proteins) in
postmenopausal women in the fg/mL range, which puts them below the limit of
quantitation (LOQ) of routine assays [118, 119]. Therefore, estrogens are quantified as a
mixture of non-conjugated free and non-conjugated protein-bound forms. Typical serum
concentrations of only 2.7-15.9 pg/mL for estradiol and 11.8-37.4 pg/mL for estrone in
postmenopausal women [120-127] (Table 2.1) are still very challenging for most LCMS-based procedures. Concentrations of non-conjugated free forms are determined by
analyzing the amount of plasma steroid binding protein [128] and subtracting the amount
of each individual non-conjugated estrogen calculated to non-covalently bind to this
protein [129, 130]. Clearly, estrogen assays with high sensitivity, specificity, and
reproducibility are required in order for meaningful data to be obtained for
postmenopausal women [131]. There are three major bioanalytical methods currently in
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use: radioimmunoassay coupled with chromatography [132], gas chromatographyselected reaction monitoring/mass spectrometry (GC-SRM/MS) [133], and stable isotope
dilution liquid chromatography (LC)-SRM/MS [134]. There is increasing reliance on the
use of LC-SRM/MS-based methodology because of the relative simplicity of the triple
quadrupole instruments that are employed and the potential for future increased
specificity by coupling LC with high-resolution ion-trap-based instruments [135, 136].
For reliable measurements of multiple non-conjugated estrogens in plasma or
serum, it is necessary to employ stable isotope internal standards, which have identical
physical properties to the endogenous metabolites, but differ only in mass. Losses that
occur during the extraction and chromatographic analysis are then compensated for
because the ratio of each endogenous analyte to its internal standard remains the same.
Stable isotope analogs also act as carriers to prevent selective losses of trace analytes
through binding to active surfaces during extraction and analysis [137]. Until recently,
this ideal condition was not possible for estradiol and its metabolites because only
deuterated analogs were available for use as internal standards. Deuterated internal
standards are not ideal as they can separate from the corresponding endogenous analyte,
with a potential for differential suppression of their ESI signals and inaccurate
quantification. The availability of many [13C6]-estrogen analogs from Cambridge Isotope
Laboratories (Andover, MA) provides internal standards that do not suffer from this
potential problem.
Unfortunately, endogenous non-conjugated estrogens in postmenopausal serum or
plasma cannot be quantified using conventional electrospray ionization (ESI) or
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atmospheric pressure chemical ionization (APCI) methodology. Therefore, it is
necessary enhance the ionization characteristics of estrogens by first converting them to
suitable derivatives. Three approaches to enhancing the sensitivity of LC-ESI/MS-based
estrogen analysis through derivatization have been reported. The first approach, which
we employed originally involves the preparation of an electron capturing
pentafluorobenzyl (PFB) derivative of the estrogen coupled with the use of electron
capture atmospheric pressure chemical ionization (ECAPC)/MS [138]. The Higashi
group has also explored the utility of ECAPC/MS for estrogen analysis by using different
electron capturing derivatives [139]. We showed that it was possible to quantify
estrogens in the low pg/mL range in plasma using LC-ECAPCI/MS [140]. The second
approach, which has much wider utility, involves the use of derivatives that enhance the
ESI signal, a strategy that greatly improves sensitivity during LC-ESI/MS analysis. This
approach is exemplified by studies from the Singh [141], Tai [142], Ziegler [143], and
Kushnir [134] groups who used the dansyl (D) derivative to improve sensitivity of
detection of non-conjugated estrogens from human biofluid samples (Figure 2.1).
Alternative derivatives that have been employed include picolinoyl (P) by the Yamashita
group [144] and pyridyl-3-sulfonyl (PS) by Spink group [145] group (Figure 2.1). The
third approach involves the preparation of pre-ionized (quaternized) derivatives, so that
ionization is not required in the ESI source of the mass spectrometer. This approach was
reported in studies by the Chen [146], Adamec [147] and Higashi [148] groups in which
N-methyl-2-pyridyl (NMP), N-methyl-nicotinyl (NMN) or 1-(2,4-dinitro-5-fluorphenyl4,4,-dimethylpiperaziny (MPPZ) derivatives, respectively were attached to the 3-hydroxy
phenolic moiety of the estrogen (Figure 2.1). Our group has also used pre-ionized
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Figure 2.1: Derivatives used to enhance the ionization efficiency of estrogens in
order to improve sensitivity for LC-MS/MS analysis
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derivatives to improve sensitivity by adding a Girard P (GP) derivative to the 17-oxo
moiety of estrone and itsmetabolites [124] or by adding a Girard T (GT) derivative to the
17-oxo-moiety of androgens [149] (Figure 2.1). We have also recently developed the
pre-ionized N-methyl-3-sulfonyl-pyridinium (NMPS) derivative that can be used for both
estradiol and estrone metabolites (Figure 2.1).
The concentrations of non-conjugated estradiol in the serum of postmenopausal
women determined by LC-SRM/MS were reported to be the range of 2.7 to 15.9 pg/mL
with a mean value of 7.3 pg/mL (Table 2.1). Concentrations of serum estrone that were
also determined by LC-SRM/MS were reported to be significantly higher – in the range
11.8 to 37.4 pg/mL with a mean value of 22.8 pg/mL (Table 2.1). These values are in
reasonable agreement with those obtained for estradiol in the serum of postmenopausal
women (mean 5.1 pg/mL, range 2.9 to 7.3 pg/mL) [133, 150-152] and serum estrone
(mean 15.2 pg/mL, range 12.7 to 17.6 pg/mL) [151, 152] using high sensitivity GCSRM/MS. This suggests that values in excess of 15 pg/mL for estradiol and 30 pg/mL
for estrone should treated with extreme caution. LC-SRM/MS studies that analyzed nonconjugated serum 16α-hydroxy-estradiol reported levels that were quite consistent with a
mean value of 9.7 pg/mL and a range of 7.7 to 13.5 pg/mL (Table 2.1). In contrast, two
studies have reported 16α-hydroxy-estrone concentrations to be in a similar range (10.7
to 11.2 pg/mL) whereas two additional studies reported 16α-hydroxy-estrone to be below
the limit of quantification (Table 2.1). It is noteworthy that the highly sensitive method
based on a GP derivative, which has a limit of quantification of 0.15 pg/mL for 16αhydroxy-estrone was unable to detect any of this analyte [124]. This suggests that
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Table 2.1. Concentrations of non-conjugated estrogens in postmenopausal serum
determined by LC-SRM/MS

Reference
Concentration

Xu 2007
[19]

Caron
2009 [20]

Mean
pg/mL

Mean
pg/mL

Gao 2010 Walsh 2011
[21]
[22]
Mean
pg/mL

Median
pg/mL

Rangiah
2011 [23]

Rothman
2011 [24]

Mean
pg/mL

Mean
pg/mL

Fuhrman
Falk
2012 [25] 2013 [26]
Median
pg/mL

Median
pg/mL

Overall
Mean
pg/mL

E2

15.0

6.6

15.9

3.4

x

3.1

4.2

2.7

7.3

E1

32.7

32.3

x

18.4

12.3

37.4

14.6

11.8

22.8

16α -OH-E2

7.9

x

x

x

x

x

13.5

7.7

9.7

16α -OH-E1

BLQ

x

x

x

BLQ

x

11.2

10.7

10.9

2-OH-E2

BLQ

x

x

x

x

x

BLQ

BLQ

BLQ

2-OH-E1

BLQ

x

x

x

x

x

BLQ

BLQ

BLQ

4-OH-E2

x

x

x

x

x

x

x

x

x

4-OH-E1

BLQ

x

x

x

x

x

BLQ

BLQ

BLQ

2-MeO-E2

BLQ

x

x

x

x

x

1.4

0.7

1.0

2-MeO-E1

BLQ

x

x

x

2.7

x

2.3

4.6

3.2

4-MeO-E2

BLQ

x

x

x

x

x

BLQ

BLQ

BLQ

4-MeO-E1

BLQ

x

x

x

BLQ

BLQ

BLQ

BLQ

x = not analyzed
Abbreviations: BLQ = below lower limit of quantitation; E2 = estradiol; E1 = estrone;
OH = hydroxy; MeO = methoxy.
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trace amounts of interfering substances could be responsible for the very low
concentrations of the non-conjugated hydroxylated estrogens that have been reported and
that the results of these studies should be re-evaluated with assays capable of more
sensitive detection. The non-conjugated catechol estrogens (2- and 4-hydroxy-estradiol,
2- and 4-hydroxy-estrone) represent very challenging analytical targets because of their
inherent instability. Most of the LC-SRM/MS studies have reported very low or
undetectable amounts of these unstable analytes in serum (Table 2.1). Similarly, the
non-conjugated methoxy-estrogens all appear to be present at levels that are below the
limit of quantification of most LC-SRM/MS assays (0.7 to 4.6 pg/mL; Table 2.1).
The concentrations of non-conjugated estradiol in the serum of postmenopausal
women determined by LC-SRM/MS were reported to be the range of 2.7 to 15.9 pg/mL
with a mean value of 7.3 pg/mL (Table 2.1). Concentrations of serum estrone that were
also determined by LC-SRM/MS were reported to be significantly higher – in the range
11.8 to 37.4 pg/mL with a mean value of 22.8 pg/mL (Table 2.1). These values are in
reasonable agreement with those obtained for estradiol in the serum of postmenopausal
women (mean 5.1 pg/mL, range 2.9 to 7.3 pg/mL) [133, 150-152] and serum estrone
(mean 15.2 pg/mL, range 12.7 to 17.6 pg/mL) [151, 152] using high sensitivity GCSRM/MS. This suggests that values in excess of 15 pg/mL for estradiol and 30 pg/mL
for estrone should treated with extreme caution. LC-SRM/MS studies that analyzed nonconjugated serum 16α-hydroxy-estradiol reported levels that were quite consistent with a
mean value of 9.7 pg/mL and a range of 7.7 to 13.5 pg/mL (Table 2.1). In contrast, two
studies have reported 16α-hydroxy-estrone concentrations to be in a similar range (10.7
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to 11.2 pg/mL) whereas two additional studies reported 16α-hydroxy-estrone to be below
the limit of quantification (Table 2.1). It is noteworthy that the highly sensitive method
based on a GP derivative, which has a limit of quantification of 0.15 pg/mL for 16αhydroxy-estrone was unable to detect any of this analyte [124]. This suggests that trace
amounts of interfering substances could be responsible for the very low concentrations of
the non-conjugated hydroxylated estrogens that have been reported and that the results of
these studies should be re-evaluated with assays capable of more sensitive detection. The
non-conjugated catechol estrogens (2- and 4-hydroxy-estradiol, 2- and 4-hydroxyestrone) represent very challenging analytical targets because of their inherent instability.
Most of the LC-SRM/MS studies have reported very low or undetectable amounts of
these unstable analytes in serum (Table 2.1). Similarly, the non-conjugated methoxyestrogens all appear to be present at levels that are below the limit of quantification of
most LC-SRM/MS assays (0.7 to 4.6 pg/mL; Table 2.1).

2-4: Conjugated estrogens
Two approaches have been employed for the analysis of conjugated estrogens.
The first approach involves hydrolysis of the β-glucuronide and sulfate conjugates with
β-glucuronidase/arylsulfatase (G/S) such as that purified from helix pomatia, followed by
derivatization using one of the derivatives in shown Figure 2.1 and LC-SRM/MS
analysis. Analytical data are often reported as total (T) values, which is the sum of the
non-conjugated and conjugated estrogens (Table 2.2). The second approach involves
analysis of the intact conjugate without G/S hydrolysis or derivatization using negative
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ESI-based LC-MS methodology. Each method has drawbacks and for many of the
conjugated estrogens rigorous stable isotope dilution methodology cannot be employed
because appropriate standards are not available. The use of G/S hydrolysis for all of the
conjugates (except estradiol and estrone where appropriate standards are available) is
dependent upon the assumption that quantitative conversion of the conjugates occurs.
Non-conjugated heavy isotope standards can compensate for any decomposition of the
endogenous estrogens that occurs during the hydrolysis procedure. It is more
problematic that no authentic standards are available for many of the potential βglucuronide and sulfate estrogen conjugates. Furthermore, no systematic studies have
been conducted to evaluate which conjugates are present in postmenopausal serum and
whether they are completely hydrolyzed by the typical β-glucuronidase/sulfatases that are
employed. One way to provide assurance that hydrolysis is complete is to conduct a
separate methanolysis of the sample with anhydrous hydrogen chloride in methanol
[153]. The concentrations of non-conjugated estrogens that are determined can then be
compared with those obtained from G/S hydrolysis [154, 155].
In general, very few heavy isotope internal standards are available for rigorous
quantification of estrogen conjugates. A heavy isotope internal standard for estrone-3sulfate (2,4,16,16-[2H4]-estrone-3-sulfate) is commercially available from C/D/N isotopes
(Pointe-Claire, CA) so that reliable quantitative assays can be conducted for this
important analyte [123, 156]. It is surprising that this standard has not generally been
used for quantitative determinations of estrone-3-sulfate in the serum of postmenopausal
women. When conducting quantitative determinations, care has to be taken with
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calibration standards because both unlabeled and labeled estrone-3-sulfate contain Tris as
a stabilizer as well as significant amounts of water [156]. Quantifying the actual amount
of estrone-3-sulfate in solutions requires UV spectrophotometry, in which the λmax of
estrone at 270 nM (ε 2000) is measured [157]. Three regioisomeric heavy isotope
labeled estradiol β-glucuronides ([2H4]-estradiol-3β-glucuronide, [2H4]-estradiol-17-βglucuronide, [2H4]-estradiol-3,17-bis-β-glucuronide) have been synthesized using rat liver
microsomes and used as internal standards in LC-SRM/MS assays for the corresponding
endogenous β-glucuronides [121, 123]. No heavy isotope internal standards are available
for any of the other estrogen conjugates that have been analyzed (Table 2.2).
The very low concentrations of non-conjugated estradiol in the serum of
postmenopausal women are reflected in the low level of total (non-conjugated +
conjugated) serum estradiol with a mean value of 26.3 pg/mL and a range of 6.2 to 51.5
pg/mL [120-123, 126, 127, 151, 152, 158-160] (Table 2.2). The reported mean levels of
estradiol-3β-glucuronide of 5.5 pg/mL suggest that the sulfate conjugate is probably also
present in the serum. Recent studies have found total mean estrone concentrations to be
176.6 pg/mL with a range of 61.3 to 442.1 pg/mL (Table 2.2). However, specific
analyses of estrone-sulfate (137 to 440 pg/mL) and estrone-3β-glucuronide (22.6 to 33.9
pg/mL) suggest that some of the total estrone conjugate values obtained after G/S
hydrolysis might be an underestimate of the true values (Table 2.2). Therefore, future
studies should focus on the analysis of intact estrone-sulfate using stable isotope LCSRM/MS methodology [123, 156]. This approach would be particularly useful for
monitoring the effect of aromatase inhibitors [161].
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Table 2.2. Concentrations of conjugated and total estrogens in postmenopausal
serum determined by LC-SRM/MS

Reference

Xu 2007
[19]

Technique

G/S

Intact

Intact

G/S

Intact

G/S

G/S

Intact

G/S

G/S

G/S

Mean
pg/mL

Mean
pg/mL

Mean
pg/mL

Mean
pg/mL

Mean
pg/mL

Mean
pg/mL

Mean
pg/mL

Median
pg/mL

Median
pg/mL

Median
pg/mL

Median
pg/mL

Mean

51.5

x

x

31.6

x

48.3

x

x

9.8

6.2

10.5

26.3

x

x

x

x

8.4

x

x

2.5

x

x

x

5.5

442.1

x

x

196.7

x

x

x

x

105.5

61.3

77.3

176.6

x

x

x

x

30.9

x

x

22.6

x

x

x

26.8

x

232.0

137.0

x

440.0

x

x

170.0

x

x

x

244.8

27.9

x

x

741.6

x

x

x

x

126.0

78.4

70.5

208.9

Concentration
E2-T
E2-3G
E1-T
E1-3G
E1-S
16α -OH-E2-T

Labrie
Labrie 2008
Masi
2007 [50]
[51]
2009 [57]

Caron
2009 [20]

Gao 2010
Patel
Walsh 2011 Fuhrman Falk 2013
[21]
2011 [58]
[22]
2012 [25]
[26]

Dallal
2014 [59]

Overall

16α -OH-E1-T

8.8

x

x

26.4

x

11.5

19.4

x

11.2

10.7

8.1

13.7

2-OH-E2-T

11.1

x

x

15.9

x

12.7

x

x

10.4

6.6

3.5

10.0

2-OH-E1-T

72.5

x

x

136.4

x

69.4

x

x

19.7

21.2

17.9

56.2

4-OH-E2-T

x

x

x

x

x

x

x

x

x

x

x

x

4-OH-E1-T

11.5

x

x

BLQ

x

x

x

x

6.3

5.0

3.0

6.5

2-MeO-E2-T

BLQ

x

x

19.0

x

x

x

x

2.3

4.7

4.0

7.5

x

x

x

x

6.9

x

x

2.5

x

x

x

4.7

BLQ

x

x

32.8

x

x

x

x

3.7

12.4

8.4

14.4

2-MeO-E2-3G
2-MeO-E1-T
2-MeO-E1-3G

x

x

x

x

6.2

x

x

2.5

x

x

x

4.4

4-MeO-E2-T

BLQ

x

x

9.2

x

x

x

x

0.8

0.6

0.8

2.9

4-MeO-E1-T

BLQ

x

x

16.6

x

x

x

x

1.1

1.1

1.1

5.0

x = not analyzed
Abbreviations: BLQ = below lower limit of quantitation; E2 = estradiol; E1 = estrone;
OH = hydroxy; MeO = methoxy; T= total (non-conjugated + conjugated); G/S= βglucuronidase/arylsulfatase; -S = sulfate; -G = glucuronide
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Mean levels of total 16α-hydroxy-estradiol have been reported to be 208.9 pg/mL
with a wide range of 27.9 to 741.6 pg/mL. However, more recent reports suggest that the
actual range may be closer to 70.5 to 126.0 pg/mL (Table 2.2). Levels of total 16αhydroxy-estrone were reported as being much lower (mean 13.7 pg/mL, range 8.1 to 26.4
pg/mL) (Table 2-2). These values are similar to the non-conjugated levels (Table 2.1)
adding further concern that these low levels values might simply arise from quantification
of trace amounts of interfering substances. Levels of the other total estrogen conjugates
except for 2-hydroxy-estrone were all very close to the LOQs (8 pg/mL) that have been
reported for most of the assays (Table 2.2). Therefore, care should be exercised in
interpreting these values.

Table 2.3. Concentrations of non-conjugated and conjugated androgens in
postmenopausal serum determined by LC-SRM/MS

Reference
Concentration

Labrie
Labrie
Kushnir Bui 2010 Walsh
Rothman
Haring
Methlie
Labrie
Overall
2007 [50] 2008 [51] 2010 [61]
[62]
2011 [22] 2011 [24] 2012 [63] 2013 [64] 2013 [65]
Mean

Mean

Median

Mean

Mean

Mean

Mean

Median

Mean

Mean

T (pg/mL)

x

x

180

248

140

109

x

187

x

173

AD (pg/mL)

x

x

360

x

440

x

354

367

x

380

DHEA (pg/mL)

x

x

1670

x

1910

x

x

x

x

1790

502

355

x

x

600

x

x

x

540

499

DHEA-S (ng/mL)

x = not analyzed
Abbreviations: AD, androstenedione; T, non-conjugated testosterone, DHEAS, DHEAsulfate.
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2.5: Non-conjugated and conjugated androgens
The importance of analyzing androgens stems from their potential conversion to
estrogens in breast and endometrial tissue (Figure 1.2). Consequently, a number of
studies have reported the analysis of non-conjugated testosterone, DHEA, and
androstenedione in serum samples from postmenopausal women (Table 2.3) [151, 152,
162]. Levels of non-conjugated testosterone determined by LC-SRM/MS have been
reported as a mean level of 173 pg/mL with a range of 109 to 248 pg/mL [123, 125, 151,
152, 162-166] (Table 2.3). This is slightly higher than the mean value of 107 pg/mL
(range 90-130 pg/mL) that was reported using GC-SRM/MS [123, 125, 151, 152, 163,
164, 166]. It is noteworthy that when modern very high sensitivity triple quadrupole
instrumentation was employed, the concentration of serum testosterone of 187 pg/mL
was still higher than the values reported by GC-SRM/MS [165]. The higher values for
serum non-conjugated testosterone reported by the LC-SRM/MS methods could be
overestimating the actual serum concentrations, so these values should be re-evaluated.
Doing so could involve use of derivatization procedures to improve sensitivity and
specificity [149] and/or use of high-resolution MS [135, 136]. The mean level of serum
androstenedione was reported to be 380 pg/mL with a range of 354 to 440 pg/mL (Table
2.3). These consistent values suggest that serum androstenedione concentrations in
postmenopausal women are truly in the range of 380 pg/mL. The mean level of nonconjugated DHEA was reported to be 1790 pg/mL with a range 1670 pg/mL to 1910
pg/mL (Table 2.3). In contrast to non-conjugated serum testosterone, this value agrees
well with the mean level of 1203 pg/mL obtained by GC-SRM/MS (range 720 to 1800
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pg/mL) [151, 152, 166]. The mean level of DHEA sulfate was reported to be 499 ng/mL
(range from 355 to 600 pg/mL), which is approximately five orders of magnitude higher
than the mean value of 1790 pg/mL reported for the non-conjugated form of DHEA
(Table 2.3). If the sulfate conjugate can serve as a precursor to the formation of
estrogens (Figure 1.2) this represents an enormous pool that could potentially be
eliminated by the use of sulfatase inhibitors [106]. Surprisingly, no studies have been
reported on the use of LC-SRM/MS for the analysis of conjugated testosterone in the
serum of postmenopausal women. This would be a worthwhile endeavor for the future
if indeed the sulfate conjugate can be transported into tissues and undergo hydrolysis to
provide an additional source of non-conjugated testosterone for conversion to estrone
(Figure 1.2).

2.6: Summary and future directions
The availability of a suite of derivatization procedures makes it possible to
quantify non-conjugated estrogens by LC-SRM/MS (Table 2.1) with sensitivity
comparable to that which can be obtained by GC-SRM/MS [133]. Pre-ionized
derivatives are also proving to be useful for the quantification of androgens [149],
although this methodology has not yet been applied to postmenopausal serum samples.
This suggests that in the future it will be possible to conduct LC-MS/MS assays on
multiple estrogen and androgen metabolites in serum and plasma at an order of
magnitude lower than current methodology (Table 2.1). The availability of high
sensitivity high-resolution ion trap instrumentation such as the Thermo Q-Exactive (San
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Jose, CA) should make it possible to conduct analyses with further increases in sensitivity
and specificity. Preliminary results are very encouraging with high-resolution
instruments [135, 136]. Improved specificity could also arise from the use of improved
chromatographic separations such as that which can be obtained with supercritical fluid
chromatography (SFC) [167]. The availability of modern triple quadrupole mass
spectrometers such as the Waters Xevo (Milford, MA), which are integrated with SFC
(Acquity UPC2) could prove to be very useful for routine non-conjugated estrogen
analyses. The high sensitivity that can be obtained with modern LC-SRM/MS will also
permit the use of smaller volumes of biofluids to help conserve important plasma and
serum samples. This will make it possible to use plasma and serum samples available
from existing Biobanks without significantly depleting the total volume available. This
could permit additional studies to be conducted on the same samples in order to help
understand the factors that cause an increase in breast cancer risk.
Recent LC-SRM/MS assays have revealed that true serum levels of 16α-hydroxyestrone are likely to be lower than previously reported. This should lead to re-evaluation
of the importance of this metabolite, as it has been proposed to be involved in breast
cancer progression [168-170]. Several studies were unable to detect non-conjugated
16α-hydroxy-estrone, while other studies found levels of the metabolite to be very close
to the reported limits of quantification (Table 2.1). Reported levels of non-conjugated
16α-hydroxy-estradiol are similarly very close to the limits of quantification of the assays
employed. This suggests that when these analytes are analyzed with greater sensitivity
and specificity, serum concentration will actually be closer to 1 pg/mL. Intriguingly,
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very low levels of the conjugated forms of both 16α-hydroxy-estrone and 16α-hydroxyestradiol have also been reported (Table 2.2). No methods have been developed to detect
the intact β-glucuronide and sulfate conjugates of the 16α-hydroxy estrogens and so it is
conceivable that the lack of detection could be due to incomplete hydrolysis by the G/Sbased procedures normally employed. Therefore, there is a compelling need to confirm
these findings using alternative methodology such as hydrolysis of conjugates with
anhydrous hydrogen chloride [153] rather than by G/S.
The quantification of estrone-sulfate is particularly important as it is the major
circulating form of estrone [161] and can potentially serve as a precursor to estrone in
tissues through the action of sulfatases [106]. Furthermore, estrone-sulfate could
potentially serve as a biomarker for the effectiveness of aromatase inhibitors [161]. It
should be possible to detect low pg/mL levels by stable isotope dilution LC-SRM/MS,
which would be approximately 1 % of the original circulating form, confirming complete
inhibition of estrogen biosynthesis. Stable isotope dilution LC-SRM/MS assay
methodology should be as specific as possible. Unfortunately, the only heavy isotope
internal standard available for estrone-sulfate is the tetradeuterated form. Therefore,
there is a critical need to synthesize the corresponding [13C]-analog of estrone-sulfate in
order to overcome the problems inherent to use of deuterated internal standards. The
[13C]-analog would additionally be stable to acid hydrolysis, overcoming any additional
concerns that deuterium could exchange for protium during the analytical procedure.
Significant advances have been made in the development of LC-SRM/MS assays
over the last decade, allowing increasingly sensitive and reliable quantification of serum
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estrogens and androgens. These advances in analytical methodology will facilitate the
development of improved breast cancer risk models that incorporate serum
concentrations of a comprehensive panel of estrogen and androgen metabolites. [131].
Previous studies have shown that such models have the potential to significantly improve
breast cancer prevention [112, 113]. The LC-SRM/MS assays have potential utility for
discovering biomarkers for the treatment and early detection of endometrial cancer as
exemplified in the study of Audet-Walsh et al. [123]. The ability to routinely analyze
serum and plasma estrogens and androgens with very high sensitivity and specificity by
stable isotope dilution LC-SRM/MS is a promising avenue towards saving a large
number of women from these devastating diseases [131, 171].
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CHAPTER 3: Application of rapid and highly sensitive LC-MS and LC-HRMS
assays for quantitative analysis of estrogens and androgens from various biological
matrices

3-1: Abstract
Measurement of estrogens and androgens at the low and often trace levels present in
special populations such as children and post-menopausal women remains a significant
challenge. Understanding the relationship between circulating sex steroids and breast
cancer risk, or clinical response to estrogen-suppression with aromatase inhibitors (AI)
requires highly sensitive and reliable quantitative methods. While immune-based assays
have most commonly been used to investigate such questions, they suffer from a lack of
specificity to distinguish among steroid species and thus results of studies that have relied
on such methods are called into question. Application of liquid chromatography tandem
mass spectrometry (LC-MS/MS) and liquid chromatography high resolution mass
spectrometry (LC-HRMS) provides a platform for highly sensitive and reliable
quantification of sex steroids from human biological samples at levels relevant to the low
physiological range found in post-menopausal women and women on AI. In this chapter,
I will discuss development of a rapid LC-HRMS method capable of quantifying estrone
and estradiol at levels as low as 0.195 pg/mL after extraction from 100 µL human serum.
LC-MS and LC-HRMS assays were additionally applied to explore sex steroid
metabolism in in vitro models of ER+ breast cancer, and robust quantification of sex
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steroids from both intracellular and extracellular compartments was demonstrated.
Finally, quantitative real-time PCR was applied to explore the levels of expression of two
sex steroid metabolizing enzymes, aromatase and aldo-keto reductase 1C3 (AKR1C3) in
variants of the ER+ breast cancer epithelial cell line MCF-7. Expression level under
normal growth conditions was explored as well as changes in expression level after short
and long-term estrogen deprivation in vitro.
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3-2: Introduction
As discussed in Chapter 2, stable isotope dilution liquid-chromatography / tandem
mass spectrometry (SID LC-MS/MS) assays provide a platform for sensitive and accurate
quantification of estrogens and androgens from biological matrices. This is essential for
accurately assessing physiological levels of estrogens and androgens present in special
populations, such as children, post-menopausal women or women taking aromatase
inhibitors.
LC-MS provides a vast increase in specificity compared with immune-based
methods commonly used to assess circulating levels of sex steroids [172]. A further
increase in specificity can be achieved using hybrid quadrupole / ion trap mass
spectrometers which combine the capacity for targeted selection of precursor ions with
high-resolution, accurate-mass detection [173, 174]. High resolution mass spectrometry
(HRMS) provides a further advance in specificity over tandem MS assays of estrogens
and androgens where interference is still possible using lower resolution detectors due to
the presence of multiple steroid metabolites, internal standards or fragment ions which
may have the same molecular ion. HRMS additionally allows for acquisition of an
enriched data set that includes untargeted metabolite-level information which can later be
mined for presence of other compounds of interest, such as drug metabolites.
A targeted / untargeted hybrid method has been developed for quantification of a
panel of keto-androgens extracted from biological samples [173], and in this chapter I
will discuss the adaptation of an existing tandem MS assay for quantification of estrone
and estradiol [175] to a LC-HRMS platform. These methods, along with a previously
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validated ultrasensitive nano-LC/tandem MS assay capable of quantifying trace levels of
serum estrogens [176] have been applied to quantify circulating levels of estrogens and
androgens in post-menopausal women on adjuvant AI (Chapter 6).
In this chapter, I will discuss application of these assays for quantification of
estrogens and androgens from various biological matrices, including intracellular and
extracellular steroids present in breast cancer epithelial cells grown in culture. The assays
therefore have the dual functionality of high sensitivity for accurate quantification of
estrogens and androgens at the low physiological levels present in post-menopausal
women and women on AI, and allowing studies to assess estrogen and androgen
metabolism in models of ER+ breast cancer in vitro.
MCF-7 is an ER+ breast cancer epithelial cell line which has been used
extensively to understand breast cancer biology [177]. Variants of MCF-7 have been
developed to model aromatase inhibitor therapy in breast cancer. MCF-7Aro is a variant
of MCF-7 which stably expresses aromatase, and can be used to study AI therapy in vitro
[178]. LTEDAro is a variant of MCF-7Aro that acquired the ability to grow long-term in
the absence of estrogens, and is a model of acquired resistance to AI [70, 179]. This
chapter discusses preliminary studies aimed at exploring the cell culture and analytical
conditions to allow experiments tracing androgen metabolism and estrogen formation at
relevant physiological levels in these variant cell lines, and expanding the studies to
model AI therapy in vitro.
Use of MS-based methods to quantify intracellular and extracellular metabolites
at relevant physiological levels in breast cancer cells has been limited. Some studies
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assessing estrogen formation from androgen precursors in MCF-7 cell lines either used
unreliable immune-based techniques [100], or used LC-MS/MS but lacked the sensitivity
to quantify estrogen formation at relevant physiological ranges [180, 181] A panel of
intracellular estrogen metabolites (EM) present in MCF-7 was quantified by LC-MS in
two reports [180, 182]. In the first study, endogenous intracellular metabolites were
quantified from various cancer cell lines in culture but to my knowledge this assay has
not been applied to trace formation of estrogens from precursors in breast cancer cell
lines [182]. In the second study, formation of EM from estradiol precursor was traced
both intra- and extracellularly, but the assay required a starting concentration of 1 µM
estradiol and EM were quantified in the nM range, which is far beyond physiologically
relevant levels in post-menopausal women [180]. In another report, metabolism of 100
nM DHEA and 100 nM estrone by MCF-7 cells was assessed, but the assay had a lower
limit of quantification of 140 pg/mL for estradiol, and thus was not capable of
quantifying low-level estrogen formation from precursors [181]. A study published in
2002 utilized LC-MS to trace metabolism of androgen precursors at physiological levels
in MCF-7, and reported downstream detection but not quantification of estrogen
formation from androgen precursor [98]
Modeling AI therapy in vitro requires assays with adequate sensitivity to quantify
trace levels of estrogens formed in the presence of aromatase inhibitor. Additionally,
exploring the question of whether breast cancer cells are capable of metabolizing other
androgen precursors, such as DHEA or DHEA-S to estrogens also requires use of an
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assay that can reliably quantify low levels of estrogen formation. Thus, the ability to
quantify intra- and extracellular steroids at physiologically relevant ranges is essential.
In this chapter, I will discuss application of LC-MS or LC-HRMS assays for
quantification of a panel of estrogen and androgen metabolites both intracellularly and
extracellularly at physiological ranges. I used the steroid-depleted MCF-7Aro cells as an
analytical matrix for quantification of intracellular metabolites in this cell line, and
conducted a pilot test of testosterone metabolism to estrogens +/- the third generation AI
letrozole in both intracellular and extracellular compartments. Finally, expression level of
two estrogen metabolizing enzymes, aromatase and AKR1C3, was assessed by
quantitative real-time PCR in MCF-7 and variant cell lines, and changes in expression
level of these two enzymes after short and long-term estrogen deprivation were assessed.

3-3: Materials and methods
I.

Human serum

Analysis of estrogens and androgens from human serum
Off the clot double charcoal-stripped human serum (Golden West Biologicals,
Temecula, CA) was used as an analytical matrix for quantification of keto-androgen
metabolites and estrogens from human serum. Estrogens and androgens present in 100
µL human serum underwent liquid-liquid extraction with 2.5 mL methyl-tert-butyl ether
(Sigma, St. Louis, MO) after addition of 300 µL water, 100 µL saturated NaCl and 10 µL
1N HCl. Samples were vortexed on a multi-vortexer for 20 minutes and then centrifuged
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Acetonitrile
1% triethylamine

+
Estradiol

40°C
15

FMP-TS

Estradiol-FMP
Methanol
10% acetic
acid

+
Testosterone

40°C
15

Girard’s Reagent P

Testosterone-GP

Figure 3.1. Derivatization schema for formation of estradiol-FMP and testosterone-GP
pre-ionized derivatives prior to LC-HRMS analysis

for 15 minutes at 3600xg. The upper, organic layer containing extracted estrogens or
androgens was removed and dried under nitrogen prior to chemical derivatization and
LC-MS analysis.
An internal standard mix containing isotopically-labeled standards corresponding
to analytes of interest was spiked into serum prior to extraction. Internal standard mixes
were as follows. For analysis of a keto-steroid panel conjugated with Girard’s reagent P,
internal standard mix contained [13C3]-testosterone, [13C3]-4-androstenedione, [2H6]44

dehydroepiandrosterone, and [13C6]-estrone (Cambridge Isotope labs, Tewksbury, MA).
For analysis of estrone and estradiol conjugated with 2-fluoro-1-methylpyridinium-ptoluenesulfonate (FMP-TS) reagent [175] internal standard mix contained [13C6]-estrone
and [13C6]-estradiol. For keto-steroid analysis from 100 µL human serum, calibration
curves were prepared from stock solutions of keto-steroids in the following ranges:
testosterone, 5α-androstanedione, epi-testosterone, 4-androstenedione and estrone at 3.9 –
1000 pg/mL, and dehydroepiandrosterone at 19.5 – 5000 pg/mL. For estrogen-FMP
analysis from 100 µL human serum, calibration curves were prepared from stock
solutions of estrone and estradiol in the range of 0.195 – 50 pg/mL.
LC-HRMS analysis of keto-androgens extracted from human serum was
conducted on a Thermo Q Exactive Plus coupled to an Ultimate 3000 UHPLC interfaced
with a heated electrospray ionization (HESI-II) source as previously described [173]. A
previously reported tandem MS assay for quantification of estrone and estradiol from
human serum [175] was adapted to a LC-HRMS platform as described below.
LC-HRMS analysis of estrone and estradiol as FMP-conjugates
A rapid and highly sensitive method for quantitative analysis of estrone and
estradiol from 100 µL human serum was developed by adapting a LC-MS/MS assay to a
LC-HRMS platform. The derivatization reaction proceeded as follows: 2-ﬂuoro-1methylpyridiniumptoluenesulfonate (FMP-TS) reagent was freshly prepared at 5 mg/mL
in acetonitrile containing 1% triethylamine (Sigma, St. Louis, MO). 50 µL was added to
each vial containing extracted estrogens. The mixture was vortexed for 10 seconds and
then incubated at 45°C for 15 minutes. The reaction was stopped by the addition of 50 µL
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Figure 3.2. LC-HRMS and LC-MS/HRMS of GP derivatives of (A) T, (B) DHEA, (C)
epiT (9.8) and 5α-AD (10.0), and (D) AD as the more intense bis-GP with co-elution of
their corresponding stable isotope labeled internal standards for T, DHEA and AD.
Published in A.J. Frey et al. / Steroids 116 (2016) 60-66.

46

water containing 0.1% formic acid, and 5 µL of this mixture was directly injected for LCHRMS analysis.
Analysis was conducted on a Thermo Q Exactive HF coupled to an Ultimate 3000
UHPLC interfaced with a heated electrospray ionization (HESI-II) source. Separations
were performed on a Waters Acquity UPLC BEH C18 Column (130Å, 1.7 µm, 2.1 mm x
50 mm). The gradient started at 55% B and was changed to 98% B over 5 min, held
constant for 3 minutes then back to the initial composition for equilibration of the column
for a total chromatographic separation time of 10 min. Mobile phase A was water with
0.1% formic acid, and mobile phase B was methanol with 0.1% formic acid. The
instrument was operated in positive ion mode alternating between full scan from 200-800
m/z at a resolution of 30,000 and parallel reaction monitoring at 60,000 resolution with a
precursor isolation window of 0.7 m/z. Molecular (M+) precursor ions were as follows:
Estrone: 362.2115; [13C6]-estrone: 368.2361; estradiol: 364.2271; and [13C6]-estradiol:
370.2465. The method used the separation of signal from noise based on the molecular
ion’s unique stability, by applying extra CID on the parent ion. The method first reported
by Ciccimaro et al. is called survivor scan method (SS) [183]. Selected ion monitoring
(SIM) and SS were both tested for quantification of E1 and E2, and SS was found to have
higher sensitivity for quantification of serum estrogens.
II.

In vitro metabolism studies
MCF-7 cells were obtained as an authenticated cell line from ATCC (Manassas,

VA). MCF-7 variant cell lines, MCF-7Aro and LTEDAro, were obtained from Dr.
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Shiuan Chen (City of Hope, Duarte, CA). MCF-7 variants were analyzed by short tandem
repeat (STR) profiling through ATCC’s cell line authentication service to ensure that the
variant cell lines retained identification as MCF-7 cells. Based on the STR allele
frequency both MCF-7Aro and LTEDAro were classified as a 100% exact match for
MCF-7.
MCF-7 and MCF-7Aro cells were cultured in phenol-red free RPMI 1640
medium (Invivogen, San Diego, CA) containing 10% HyClone fetal bovine serum (FBS;
GE Healthcare Life Sciences, Logan, UT) with 100 µg/mL primocin as an antimicrobial
agent (Invivogen, San Diego, CA). LTED-Aro cells were cultured in phenol-red free
RPMI 1640 medium containing 10% double charcoal-dextran stripped fetal bovine serum
(CS FBS) (Gemini Bioproducts, West Sacramento, CA) and 100 µg/mL primocin.
In vitro androgen metabolism studies were carried out in 6-well plates. Plating
density was optimized for each cell line as the density at which cells would be 60-70%
confluent at the start of the experiment after three days growth in steroid-depleted culture
medium (RPMI 1640 containing 10% CS FBS). Optimal seeding density was determined
to be as follows for MCF-7 and variants: 5x105 cells/well for MCF-7; 4x105 cells/well for
MCF-7Aro and 2.5x105 cells/well for LTEDAro.
Background estrogen and androgen levels were tested by extraction from 500 µL
CS FBS or RPMI containing 10% CS FBS with the relevant internal standards and
assessing endogenous levels found in these media. A panel of estrogens and androgens
were found to be undetectable in both of these matrices. Metabolism experiments
included a medium blank (RPMI 1640 containing 10% CS FBS) which was not incubated
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with cells and a vehicle control (RPMI 1640 containing 10% CS FBS and 0.01% DMSO)
to ensure that there was no background level of compounds of interest.
Quantitative real-time PCR
Total RNA was extracted from pellets containing 3 million MCF-7, MCF-7Aro or
LTEDAro cells using a Qiagen RNeasy Mini Kit according to manufacturer’s
instructions (Qiagen, Germantown, MD) followed by DNAse digestion to remove
genomic DNA (Qiagen, Germantown, MD). Reverse transcription to cDNA was carried
out using an Applied Biosystems High Capacity RNA to cDNA kit according to
manufacturer’s instructions (Thermo Fisher Scientific, San Jose, CA).
Real-time PCR of AKR1C3 was carried out using an isoform-specific primer set
developed and validated by the Penning lab at University of Pennsylvania [184]. The
primer sequence for AKR1C3 is forward 5’ GTA AAG CTT TGG AGG TCA C 3’ and
reverse 5’ CAC CCA TCG TTT GTC TCG T 3’. GAPDH was amplified from all cell
lines using primer sequences provided by the Penning lab: forward 5’ CAT CTC TGC
CCC CTC TGC TGA 3’ and reverse 5’ GGA TGA CCT TGC CCA CAG CCT 3’.
Amplification of CYP19A1 was conducted using a cDNA primer pair from Origene
Technologies (Rockville, MD) with the following sequence: forward 5’
GACGCAGGATTTCCACAGAAGAG 3’ and reverse 3’
ATGGTGTCAGGAGCTGCGATCA 5’. Standard Curves for AKR1C3 and GAPDH
were prepared in range of 2.5 ng/µl to 0.025 fg/µl (ten-fold dilutions). A standard curve
for CYP19A1 was prepared in the range of 1x102 – 1x107 copies / µL. Expression of
AKR1C3, GAPDH and CYP19A1 was assessed with quantitative real-time PCR
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detection by SYBR green fluorescent incorporation (Thermo Fisher Scientific, San Jose,
CA) using a MJ Research PTC-200 Thermal Cycler and a Chromo4 Real-Time PCR
detector (Bio-Rad, Hercules, CA). AKR1C3 expression was expressed as a ratio to
GAPDH expression (fg AKR1C3 / fg GAPDH) and aromatase expression was expressed
as copies aromatase / 50 ng cDNA.
Extraction and analysis of estrogens and androgens from cell culture medium
RPMI 1640 containing 10% CS FBS was utilized as a matrix for the calibration
curves used to quantify of extracted estrogens and androgens from MCF-7 and variant
cells cultured in 6-well plates. Androgens were analyzed from 500 µl aliquots of
experimental medium with addition of 100 pg heavy-labeled internal standard prior to
liquid-liquid extraction. Internal standard mix for androgen analysis contained 13C3 T,
13

C3 4-AD and D6 DHEA (Cambridge Isotope labs, Tewksbury, MA). Standard curves

were prepared from stock solutions of testosterone, 4-androstenedione ,
dehydroepiandrosterone, epi-testosterone, and 5α-androstanedione (Steraloids, Newport,
RI) in the range of 3.9 – 1000 pg/mL in RPMI containing 10% CS FBS. 50 µL saturated
NaCl and 12 µL 1 N HCl were added to medium prior to liquid-liquid extraction with 2.8
mL methyl-tert-butyl ether (Sigma, St. Louis, MO). The organic fraction was dried under
nitrogen and extracted androgens were derivatized with Girard’s reagent P (TCI America,
Portland, OR) prior to LC-HRMS analysis as previously described [173]
Estrogens were analyzed from 1 mL aliquots of experimental medium with
addition of 100 pg heavy-labeled internal standard prior to liquid-liquid extraction.
Internal standard mix for estrogen analysis included [13C6]-estradiol and [13C6]-estrone
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(Cambridge Isotope labs). Standard curves were prepared from stock solutions of
unlabeled estradiol and estrone (Steraloids) in the range of 0.78 – 400 pg/mL. 100 µL
saturated NaCl and 20 µL 1 N HCl were added to medium prior to liquid-liquid
extraction with 5 mL diethyl ether (Sigma, St. Louis, MO). The organic fraction was
dried under nitrogen and extracted estrogens were derivatized with 2-fluoro-1methylpyridinium-p-toluenesulfonate (FMP-TS) prior to LC-HRMS analysis as described
in the previous section.
Quantitative analysis of a panel of estrogen metabolites from a cell lysate matrix
The utility of using MCF-7Aro cells after three days of growth in the absence of
steroids as an analytical matrix for quantification of intracellular steroids was explored.
Extraction of intracellular steroids was undertaken using a methanol-chloroform
extraction adapted from the following report [185]. MCF-7Aro cells were plated at a
density of 4x105 cells/well in 6-well plates and allowed to grow for three days in steroiddepleted conditions (RPMI 1640 medium containing 10% CS FBS). On the third day,
cells were placed on ice and quickly washed 2x with room temperature 0.9% NaCl.
Metabolism was immediately quenched with addition of 400 µl ice cold (-80°C)
methanol per well of a 6-well plate. An equal volume of cold water was added and cells
were scraped into a 5 mL vial. The cell suspension was sonicated on ice for 10 pulses
followed by a 60 second rest, and repeated three times. Lysates were stored at -80 until
later extraction and analysis. Upon extraction, lysate was transferred to a glass vial
containing 400 µL ice cold (-80°C) chloroform. Samples were vortexed for 10 minutes
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on a multi-vortexer, followed by a 10 minute centrifugation at 3500xg. The lower organic
layer was removed, and extracted estrogens were dried under nitrogen.
For quantification of intracellular steroids, 100 pg heavy labeled internal standard
mix in methanol was added to the cells at the time of methanol quench and harvest.
Internal standard mix contained the following compounds: [13C6]-estrone, [13C6]estradiol, [13C3]-16α-hydroxy-estrone, [13C3]-estriol, [13C6]-2-hydroxy-estrone, [13C6]-4hydroxy-estrone, [13C6]-2-methoxy-estrone, [13C6]-4-methoxy-estrone, [13C6]-2-hydroxyestradiol, [13C6]-2-methoxy-estradiol, [13C6]-4-methoxy-estradiol (Cambridge Isotope
labs, Tewksbury, MA) and [2H5]-4-hydroxy-estradiol (CDN Isotopes, Pointe-Claire,
Quebec, Canada).
For extraction of a calibration curve of estrogen metabolites from a cell lysate
matrix, 100 pg internal standard mix as well as calibrant mix were added to cells at time
of methanol quench and harvest. Standard curves were prepared from stock solutions of a
panel of twelve estrogen metabolites in methanol: estrone, estradiol, 16α-hydroxyestrone, estriol, 2-hydroxy-estrone, 4-hydroxy-estrone, 2-methoxy-estrone, 4-methoxyestrone, 2-hydroxy-estradiol, 4-hydroxy-estradiol, 2-methoxy-estradiol and 4-methoxyestradiol (Steraloids, Newport, RI). A calibration curve was prepared in the range of 1.56
– 200 pg/100 µl methanol and 100 µL calibrant mix was added per well of a 6-well plate
at time of methanol quench and harvest such that the total volume of methanol used in the
quench was still equal to 400 µL. Each calibrant level was extracted from three wells of a
6-well plate and calibration curves were prepared in triplicate.
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Estrogens extracted from MCF-7Aro lysate were conjugated with pyridine-3sulfonyl chloride prior to LC-MS analysis. Estrogen-PS analysis was conducted on a
Vantage Triple Stage Quadrupole mass spectrometer (Thermo Scientific, San Jose, CA)
coupled to a Waters nanoAcquity UPLC system (Waters Corporation, Milford, MA),
interfaced with a CaptiveSpray™ ion source (Michrom Bioresources, Inc., Auburn, CA)
as previously described [176].
Pilot test of T metabolism +/- letrozole in medium and lysate
To test metabolism of 1 nM testosterone (T) by MCF-7Aro cells in the presence
and absence of the aromatase inhibitor letrozole, MCF-7Aro cells were plated at a density
of 4x105 cells/well and allowed to grow for three days prior to addition of experimental
medium. After three days, RPMI 1640 containing 10% CS FBS and 1 nM T, or 1 nM T +
1 µM letrozole was added to cells. Vehicle for addition of steroid or steroid + inhibitor to
culture medium was DMSO at a final concentration of 0.01%. Growth medium was
harvested at 24 hours and lysate was harvested after 48-hour incubation of MCF-7Aro
cells in 1 nM T, 1 nM T + letrozole (let), or vehicle only. Keto-androgens present in
growth medium were quantified as GP derivatives by LC-HRMS, and estrogens present
in growth medium were quantified as PS derivatives by nano LC - MS/MS. A panel of
intracellular estrogen metabolites was extracted from lysate of MCF-7Aro after 48-hour
incubation with T, T+let, or vehicle and extracted estrogens were conjugated with PS
reagent prior to nano LC – MS/MS analysis.
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Figure 3.3. LC-HRMS analysis of estrone and estradiol and corresponding 13C internal
standards extracted from 100 µl human serum at 1 pg/mL and 10 fg on column
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3-4: Results
LC-HRMS analysis
The derivatization scheme shown in Figure 3.1 was applied to the analysis of
estrogens and androgens from various biological matrices: 100 µL human serum, 0.5 mL
or 1 mL cell culture medium and MCF-7Aro cell lysate.
Figure 3.2 shows LC-HRMS analysis of a panel of keto-androgens conjugated
with Girard’s reagent P, a method that was validated in Frey, et al. [173]. All compounds
were baseline resolved within a 17 minute chromatographic run time, and were
monitored as both the molecular [M+] ion (precursor) and the most intense product ion,
which consisted of loss of the GP conjugate from the keto-steroids analyzed.
A rapid and highly sensitive LC-HRMS method for quantification of estrone (E1)
and estradiol (E2) as FMP conjugates was developed as an adaptation of a LC-MS/MS
method previously reported [175]. E1 and E2 were separated within a 7 minute
chromatographic run time. The molecular [M+] ion of E1, E2 and corresponding 13C
labeled internal standards was monitored with high resolution mass using a survival scan
method which was found to have higher sensitivity than selected ion monitoring (SIM)
on the same instrument. Shown in Figure 3.3 is LC-HRMS analysis of E1 and E2 as
FMP conjugates at 1 pg/mL extracted from 100 µL double charcoal stripped human
serum, and 10 fg on column. E1 and E2 exhibited a linear response between 0.195 – 50
pg/mL after extraction from 100 µL stripped human serum.
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Table 3.1. Representative parameters for calibration curves of estrogens and androgens
extracted from various biological matrices and analyzed as GP, FMP, or PS derivatives
Analytical
matrix

Human
Serum

Volume

100 µl

100 µl

Cell culture
medium*

500 µl

1 mL

Cell lysate

Analyte
Testosterone
DHEA
Epi-testosterone
5αandrostanedione
4-androstenedione
(2GP)
Estrone
Estrone
Estradiol
Testosterone
DHEA
Epi-testosterone
5αandrostanedione
4-androstenedione
(2GP)
Estrone
Estrone
Estradiol

Estrone
Estradiol
16α-hydroxyestrone
Estriol
800 µl
2-hydroxy-estrone
lysate
containing 4-hydroxy-estrone
2-hydroxy5x105
4-hydroxycells**
2-methoxy-estrone
2-methoxyestradiol
4-methoxyestradiol

Chemical
Derivative
GP
GP
GP

Range
(pg/mL)
15.6 - 1000
19.5 - 5000
15.6 - 1000

Equation

R2 value

Y = 0.001009*X + 0.0622
Y = 0.0002438*X + 0.008365
Y = 0.001191*X - 0.00542

0.9927
0.9998
0.9957

GP

15.6 - 1000

Y = 0.0008795*X - 0.003366

0.999

GP
GP
FMP
FMP
GP
GP
GP

15.6 - 1000
3.9 - 1000
0.78 - 50
0.78 - 50
7.8 - 1000
19.5 - 5000
7.8 - 1000

Y = 0.001112*X + 0.002884
Y = 0.0005221*X + 0.003368
Y = 0.0007718*X + 0.005532
Y = 0.0008646*X + 0.002539
Y = 0.002916*X + 0.005671
Y = 0.0002438*X + 0.008365
Y = 0.002066*X + 0.02571

0.997
0.9997
0.9947
0.996
0.9991
0.9998
0.996

GP

7.8 - 1000

Y = 0.002426*X + 0.01953

0.9944

GP
GP
FMP
FMP

Y = 0.004369*X + 0.01941
Y = 0.006781*X + 0.03966
Y = 0.006586*X - 0.01849
Y = 0.007208*X - 0.004064

0.9986
0.9987
0.9985
0.9993

PS
PS

7.8 - 1000
3.9 - 1000
0.78 - 400
0.78 - 400
Range
(pg/5x105
cells)
1.56 - 200
1.56 - 200

Y = 0.009865*X - 0.0004334
Y = 0.01485*X - 0.001966

0.9908
0.9925

PS
PS
PS
PS
PS
PS
PS

1.56 - 200
1.56 - 200
1.56 - 200
1.56 - 200
1.56 - 200
1.56 - 200
1.56 - 200

Y = 0.01263*X + 0.005783
Y = 0.01263*X + 0.005783
Y = 0.008232*X - 0.006782
Y = 0.01255*X - 0.01068
Y = 0.005325*X - 0.005727
Y = 0.007613*X - 0.007735
Y = 0.01879*X - 0.02024

0.9924
0.9934
0.9828
0.9925
0.9913
0.9926
0.9922

PS

1.56 - 200

Y = 0.01466*X - 0.009848

0.9925

PS

1.56 - 200

Y = 0.01419*X - 0.01038

0.9922

*Phenol red free RPMI 1640 containing 10% cs FBS and 1 mL primocin as an antimicrobial
agent
**Compounds extracted from 800 µl MCF-7Aro cell lysate after 3-days growth in steroiddepleted growth medium. Data represents an average of three replicates
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Table 3.1 shows representative parameters for calibration curves extracted from various
biological matrices, including range and coefficient of determination (R2) for estrogens
conjugated with PS or FMP and androgens conjugated with GP. Because estrone contains
a keto-group, it can additionally be monitored as a GP conjugate along with the androgen
panel. The estrogen-FMP derivative demonstrated high sensitivity for quantification of
E1 and E2 to sub-pg/mL levels from only 100 µL serum, and ample sensitivity for
quantification of low level estrogen formation in culture medium. The keto-steroid
method demonstrated linearity at physiologically relevant ranges for a panel of androgens
and E1 extracted from 100 µL serum and 0.5 mL culture medium. Sensitivity of detection
of estrone was higher using the FMP method compared with GP, but for certain
applications it is useful to be able to quantify estrone within the same workflow and
analytical platform as its androgen precursors.
Quantitative analysis of estrogen metabolites extracted from MCF-7Aro cell lysate
A mix of heavy-isotope internal standards corresponding to a panel of estrogen
metabolites (EM) was spiked into and extracted from MCF-7Aro cells after three days of
growth in steroid depleted conditions (RPMI containing 10% cs FBS). No endogenous
EM were detected after extraction and LC-MS analysis, and thus utility of using MCF7Aro cells grown under steroid-depleted conditions as a matrix for quantification of
intracellular metabolites was explored.
Calibration curves were prepared by spiking in EM, calibrants and corresponding
internal standards at the time of methanol quench and cell harvest. The calibration curve
was extracted from lysate matrix in triplicate by spiking each calibrant into 3 wells of a 657

well plate and performing separate extractions. Figure 3.4 shows the average of three
calibration curves for estradiol extracted from MCF-7Aro lysate matrix and analyzed as a
PS conjugate by nano LC-MS/MS. This analyte demonstrated linearity between 1.56 –
200 pg extracted per 5x105 cells, and the curves were overlaid (the calibration curve in
figure 3-4 includes error bars for triplicate analysis). Range and R2 values for a panel of
EM including catechol and methoy-metabolites of E1 and E2 similarly extracted in
triplicate from a MCF-7Aro lysate matrix are shown in Table 3.1. R2 values were greater
than 0.99 for all metabolites with the exception of 2-hydroxy-estrone (R2 = 0.9828).
The endogenous level of estradiol in MCF-7Aro under normal growth conditions
(RPMI containing 10% regular FBS) was assessing using the calibration curve extracted
from cell lysate matrix. MCF-7Aro was found to contain 1.15 pg estradiol / 5e5 cells, and
when estradiol was extracted from cell pellets containing a range of 2.5x105 – 4x106
cells, the average level of estradiol calculated per cell remained roughly consistent (an
average of 2.6 ag/cell) (Figure 3.5). Further, the total amount of estradiol extracted from
a range of starting cell counts in MCF-7Aro exhibited a linear response (R2 = 0.9939;
Figure 3.5).
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Figure 3.4. Representative calibration curve of estradiol-PS
extracted from 800 µl MCF-7Aro lysate after three day serum
deprivation

15

R2 0.9939
10

5

0
0

1 10 6

2 10 6

3 10 6

4 10 6

Cell number

Figure 3.5. Endogenous levels of estradiol present in MCF-7Aro lysate at various cell
counts under normal growth conditions
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Pilot test of estrogen formation from androgen precursor in MCF-7Aro culture medium
and lysate
To test the applicability of LC-MS assays for quantitative analysis of androgen
metabolism and estrogen formation both intra- and extracellularly, MCF-7Aro cells were
grown for three days under steroid-depleted conditions and then treated with 1 nM
testosterone (T) (Figure 3.6A). Analysis of culture medium over 48 hours demonstrated
rapid T metabolism which corresponded to rapid formation of estradiol, with a maximum
level of 210 pg/mL (0.78 nM) E2 formed at 24 hours. Formation of E1 from T precursor
reached 5.9 pg/mL at 24 hours and 10.4 pg/mL after 48 hour incubation. Letrozole was
found to completely inhibit estradiol formation at 24 hours, and reduce the level of
estrone present in culture medium to 1.2 pg/mL (Figure 3.6A). Cell lysate was harvested
after 48-hour incubation with T or T + letrozole (Figure 3.6B). After 48-hour incubation
with 1 nM T, 15 pg estradiol was extracted from 5x105 cells, and in the presence of
letrozole intracellular E2 was decreased to <0.5 pg / 5x105 cells (Figure 3.6B).
Quantitative real-time PCR analysis of enzyme expression changes with serum
deprivation in variants of MCF-7
Endogenous expression level of two sex steroid metabolizing enzymes was examined by
quantitative real-time PCR in MCF-7, MCF-7Aro and LTEDAro (Figure 3.7A and
3.7C). Changes in expression of these two enzymes over three days of growth in steroid
depleted conditions was examined in MCF-7Aro (Figure 3.7B and 3.7D). This analysis
was not repeated in LTEDAro because this cell line is cultured under steroid-depleted
conditions.
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Figure 3.6. Pilot test of testosterone metabolism +/- letrozole in MCF-7Aro culture
medium and lysate. (A) Rapid metabolism of 1 nM testosterone and rapid formation of
estradiol or estrone in culture medium of MCF-7Aro over 48 hours, +/- letrozole at 24
hours and (B) quantification of estradiol from MCF-7Aro cell lysate +/- letrozole at 48
hours

Consistent with literature, MCF-7 was found to have a very low level of
expression of aromatase, and higher levels were quantified in the aromataseoverexpressing cell models MCF-7Aro and LTEDAro (Figure 3.7A) [178]. Aromatase
expression was found to increase over three days of serum deprivation in MCF-7Aro
(Figure 3.7B). The expression level of AKR1C3 was found to be extremely low in MCF7 and MCF-7Aro, and significantly higher in LTEDAro under normal growth conditions
(Figure 3.7C). AKR1C3 expression in MCF-7Aro was found to increase over three days
of serum deprivation (Figure 3.7D).
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Figure 3.7. Quantitative real-time PCR determination of CYP19A1 and AKR1C3
expression in MCF-7 variant cell lines. (A) CYP19A1 expression at baseline in MCF-7
and variants, expressed as copies aromatase / 50 ng cDNA. (B) Modulation of CYP19A1
expression over three days of serum deprivation in MCF-7Aro. (C) AKR1C3 expression
at baseline in MCF-7 and variants, expressed as ratio of AKR1C3 / GAPDH mRNA
expression (fg/fg). (D) Modulation of AKR1C3 expression over three days of serum
deprivation in MCF-7Aro.
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3-5: Discussion

Application of LC-MS/MS and LC-HRMS assays for sensitive and accurate
quantification of a variety of estrogens and androgens extracted from human serum, cell
culture medium or cell lysate was reported. A novel LC-HRMS assay capable of rapid
and highly sensitive quantification of E1 and E2 from human biological samples has been
developed. The assay could detect as low as 0.195 pg/mL E1 or E2 extracted from 100 µl
human serum. This represents a significant increase in sensitivity over the limit of
detection reported in the original study of 1 pg/sample or 200 fg on column, and which
required starting serum volumes of 0.5 – 2 mL [175]. Assay validation is in progress to
determine the lower limit of quantification of the assay but consistent linearity of E1 and
E2 standards extracted from 100 µl serum in the low range of 0.195 – 50 pg/mL has been
demonstrated.
The cell culture studies detailed in this chapter demonstrate that highly sensitive
LC-MS/MS and LC-HRMS assays can be applied to trace estrogen and androgen
metabolism at low physiological range in both intra- and extracellular compartments of
breast cancer cells grown in culture. Quantitative analysis of sex steroid metabolism at
physiological levels in breast cancer cells lines has not been frequently demonstrated, as
sensitivity to detect low level estrogen formation that would be relevant to the
physiological range found in post-menopausal women is challenging. The cell
metabolism pilot test presented here (Figure 3.6) demonstrated that rapid metabolism of
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testosterone to estrogens and the extent to which an AI suppressed the conversion can be
assessed both intracellularly and extracellularly in cell models of ER+ breast cancer.
MCF-7Aro lysate grown under steroid-depleted conditions was used as an
analytical matrix for quantification of intracellular metabolites in the same cell line. This
technique ensures that calibration curves can be extracted from a matrix with the same
properties as the cell lysate from which intracellular metabolites will be quantified. A
panel of EM spiked into and extracted from this matrix exhibited a linear response in the
range of 1.56 – 200 pg / 5x105 cells, and analysis of EM as PS-conjugates allowed for
inclusion of catechol-estrogens, which are difficult to analyze due to their highly reactive
and unstable nature. Application of this method would be useful for assessing EM
formation and biological activity in various breast cancer cell lines.
Changes in expression level of both aromatase and AKR1C3 was observed in
MCF-7Aro over three days of serum deprivation, and LTEDAro was found to have
significantly higher endogenous expression of AKR1C3. AKR1C3 has been found to be
over-expressed in breast cancer [43], and the increased expression observed in vitro after
both short and long-term estrogen deprivation is interesting to consider in light of the
concepts of intracrinology, whereby breast tumors can modulate local sex steroid
metabolism to enhance local estrogen formation when faced with systemic estrogen
deprivation [46].
For subsequent studies assessing AI potency in vitro, a 24-hour drug treatment
was chosen, as rapid formation of estrogen from precursors can be observed in this time
frame, and it further reflects a daily dose of AI. After these initial experiments, a rapid
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and comprehensive assessment of biochemical potency of third generation AI in MCF-7
variant cell lines was conducted in the cell culture medium only as almost all of the
estradiol formed from T precursor was secreted (Chapter 4).
The experiments detailed in this chapter were the exploratory experiments for
more comprehensive analysis of biochemical potency of third-generation AI in cell
models of AI therapy and resistance (Chapter 4), quantitative analysis of DHEA and
DHEA-S metabolism in in vitro models of ER+ breast cancer (Chapter 5) and
quantification of estrogens and androgens in serum of women taking adjuvant AI after
breast cancer (Chapter 6).
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CHAPTER 4: Exploring potency of third generation aromatase inhibitors in in vitro
models of aromatase inhibitor therapy and resistance

4-1: Abstract
Targeting aromatase is a highly effective therapeutic strategy to treat estrogen receptor
(ER) positive breast cancer after menopause. However, resistance, which can be either
inherent or acquired, is a significant problem and few studies have examined whether
resistance is related to the potency of individual aromatase inhibitors (AIs). In this study,
highly sensitive and specific stable isotope dilution liquid chromatography-high
resolution mass spectrometry (LC-HRMS) methods were utilized to quantify estrogens
and androgens. This made it possible to explore the effects of third-generation AIs using
MCF-7Aro and LTEDAro cell lines as models of AI-responsive vs. AI-resistant breast
cancer. MCF-7Aro is an ER+ MCF-7 cell line in which aromatase is overexpressed,
whereas LTEDAro is a derivative of MCF-7Aro, which has adapted to growth in the
absence of 17β-estradiol. Metabolism of ∆4-androstenedione (4-AD) and testosterone to
estrone and 17β-estradiol was analyzed in culture media of MCF-7Aro and LTEDAro in
the presence or absence of AI. Results from LC-HRMS metabolism studies were
correlated with proliferation responses to androgens, AIs or fulvestrant, a selective
estrogen-receptor degrader (SERD). LC-HRMS analyses coupled with the corresponding
growth assays revealed substantial differences in biochemical potency of third-generation
AI in vitro, with letrozole consistently found to have the greatest potency for inhibiting
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cell growth and suppressing estrogen formation from androgen substrates. Rapid LC-MS
assays, such as the LC-HRMS assays employed in the present study, can provide
sensitive and accurate information about the degree to which serum estrogens are
suppressed at the onset of AI therapy, identify non-responders and allow studies
investigating the relationship between level of suppression of serum estrogens and
relapse on adjuvant AI.
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4-2: Introduction

Targeting aromatase is a highly effective therapeutic strategy to treat estrogen
receptor (ER) positive breast cancer after menopause. In post-menopausal women,
estrogens are formed locally in breast tissue from circulating adrenal androgens [47].
CYP19 aromatase catalyzes the conversion of circulating androgens to estrogens at the
site of the tumor and has been found to be over-expressed in clinical breast cancer [30,
186, 187]. Since the early 2000s, aromatase inhibitors (AIs) have been approved as a first
line of therapy in both primary and metastatic breast cancer [51, 188]. Third-generation
AIs include the non-steroidal letrozole and anastrozole, triazole derivatives which
reversibly bind aromatase outside of the active site of the enzyme, and exemestane, an
analog of ∆4-androstenedione (4-AD) which irreversibly binds the active site as a suicide
inhibitor of aromatase [48].
Despite the efficacy of AIs, patients present with both intrinsic and acquired
resistance to AI, with risk for relapse continuing up to 15 years after initial diagnosis [48,
189, 190]. Mechanisms of resistance can vary widely among individuals and are not
completely understood [191]. A lack of cross-resistance between the non-steroidal and
steroidal AIs has been demonstrated in women on adjuvant therapy, although there is
currently no clear explanation for the mechanism behind this clinical observation [192]. A
significant proportion of research into mechanisms of resistance to AI is aimed at
understanding growth factor receptor cross-talk and the transition to ligand-independent
ERα activity, which can allow for what is considered to be estrogen-independent tumor
growth [58, 64]. While these changes have been documented, such models fail to take
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into account inadequate inhibition of aromatase systemically, or at the site of the tumor,
or the capacity of the breast tumor to modulate its local sex steroid metabolism when
presented with systemic estrogen deprivation [46].
Studies assessing serum and tissue estrogen levels after treatment with thirdgeneration AIs have demonstrated substantial differences in potency of whole-body and
tissue-specific aromatase inhibition [80, 193, 194]. Despite these findings, the connection
between individual AI response and intrinsic or acquired resistance remains unexplored.
While circulating levels of sex steroids have been associated with breast cancer risk [195,
196], studies relating serum levels of sex steroids with relapse are extremely limited
[197]. Reliable quantification of estrogens at levels present in women after menopause,
and with AI therapy is extremely challenging. Radioimmunoassay or ELISA-based
methods for steroid quantification have most commonly been used to assess breast cancer
risk and to track AI efficacy, but such methods lack the specificity to be reliable
indicators of serum sex steroid levels due to cross-reactivity with other compounds of
similar structure [73]. These methods have been found to be particularly problematic for
measuring estradiol [74-76]. Gas chromatography (GC) or liquid chromatography (LC) mass spectrometry (MS) based methods are more reliable [82, 176] however, routine
monitoring of AI therapy with reliable MS-based methods has not been applied in the
clinical setting.
Cell-based models have been developed to mimic AI therapy in vitro and
investigate mechanisms of resistance to third-generation AI. The MCF-7Aro cell line was
formed by stable expression of aromatase in MCF-7 and serves as an in vitro model of
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aromatase-overexpression in breast cancer [55]. A long-term estrogen deprived MCF7Aro cell line (LTEDAro) was formed from MCF-7Aro cells adapting to growth longterm in the absence of estrogens. LTEDAro serves as a model of acquired resistance to
AI [56]. These cell lines have been used to investigate AI potency and AI resistance
mechanisms both in vitro [57, 198-200] and in a nude mouse xenograft model [201, 202].
The purpose of this study was to quantitatively examine the metabolism of
androgen precursors to estrogens in the presence of third generation AI in MCF-7Aro and
LTEDAro. Highly sensitive and specific stable isotope dilution liquid chromatographyhigh resolution mass spectrometry (LC-HRMS) methods were used to quantify a panel of
keto-androgens [173] and estrone and estradiol (See Figures 3.1 to 3.3). Metabolism of 1
nM testosterone (T), and 1 or 5 nM 4-AD was chosen to represent median or moderately
high physiological levels of androgens in women with breast cancer. 4-AD has been
quantified from healthy post-menopausal women’s serum or plasma at a mean
concentration of 1.33 nM and T has been quantified at a mean level of 0.6 nM using LCMS methods [83]. While elevated serum androgen levels have been found to be
associated with risk of breast cancer [195, 203], studies exploring this association have
mostly utilized immunoassay or RIA. The baseline variability of androgen levels in
women with breast cancer prior to AI therapy has not been characterized using GC or
LC-MS based methods. In a cohort of 649 women with early breast cancer, plasma 4-AD
levels were reported at a mean level of 1.47 nM (interquartile range 1.02-1.97 nM, total
range 0-8.62 nM), and plasma T levels were reported at a mean level of 0.5 nM
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(interquartile range 0.03-0.72 nM, total range 0-4.26 nM) after quantification by GC-MS
[68].
In this study, quantitative analysis of estrogen formation the presence of AI has
been correlated with cellular proliferation of MCF-7Aro and LTEDAro in the presence of
AIs or the selective estrogen receptor degrader (SERD) fulvestrant. As a SERD, the mode
of action of fulvestrant is potentially complementary to AI. This study includes an
investigation of growth response to fulvestrant or fulvestrant-AI combination in MCF7Aro and LTEDAro.

4-3: Materials and methods

Cell culture
MCF-7Aro and LTED-Aro cells were obtained from Dr. Shiuan Chen City of Hope,
Duarte, CA. MCF-Aro Cells were cultured in phenol-red free RPMI medium (Invivogen,
San Diego, CA) containing 10% HyClone fetal bovine serum with 100 µg/mL primocin
as an antimicrobial agent (Invivogen, San Diego, CA). LTED-Aro cells were cultured in
phenol-red free RPMI 1640 medium containing 10% double charcoal-dextran stripped
fetal bovine serum (CS FBS) (Gemini Bioproducts, West Sacramento, CA) and 100
µg/mL primocin.

Proliferation assays
Cell proliferation was assessed using the XTT cell proliferation assay kit (ATCC,
Manassas, VA). MCF-7Aro cells were diluted to a final concentration of 7810 cells/mL
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and 100 µL cell suspension was added per well of a 96-well plate. Cells were allowed to
grow for three days in serum-deprived conditions (RPMI 1640 medium containing 10%
CS FBS) prior to addition of experimental medium. Vehicle for all experiments was
DMSO at a final concentration of 0.01%. Upon addition of experimental medium, cells
grew for an additional 10 days prior to taking absorbance readings at 475 nm and 660 nm
according to manufacturer’s recommendations. LTEDAro cells were diluted to a final
concentration of 3000 cells/mL in RPMI 1640 containing 10% CS FBS and 100 µL cell
suspension was added per well of a 96-well plate. Cells were allowed to grow for two
days prior to addition of experimental medium, and then grew an additional 10 days prior
to analysis. Experiments were conducted in biological triplicate with similar results.

Cellular androgen metabolism and AI treatment
MCF-7Aro cells were seeded at 4x105 cells/well of a 6-well plate in steroid-depleted
conditions (RPMI 1640 medium containing 10% CS FBS) and allowed to grow for three
days prior to addition of experimental medium. LTEDAro cells were similarly plated at a
density of 2.5x105 cells/well of a 6-well plate. Experimental medium formulations were
made by adding individual steroids or steroid + drug combinations to RPMI 1640
containing 10% CS FBS. Vehicle for all experiments was DMSO at a final concentration
of 0.01%. Background sex steroid levels in CS FBS were assessed by quantifying a panel
of estrogens and androgens by LC-MS. All compounds were undetectable in undiluted
CS FBS, making RPMI 1640 containing 10% CS FBS a suitable matrix for assessment of
individual sex steroid metabolism in MCF-7Aro and LTEDAro. Metabolism of the
following compounds was assessed in two cell lines: 1 nM T, 1 nM 4-AD, 1 nM T + 1
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µM letrozole, 1 nM T + 1 µM anastrozole, 1 nM T + 1 µM exemestane, 1 nM 4-AD + 1
µM letrozole, 1 nM 4-AD + 1 µM anastrozole, and 1 nM 4-AD + 1 µM exemestane.
Rapid metabolism of T and 4-AD was assessed by harvesting experimental medium after
1-hour, 4-hour, 16-hour and 24-hour incubation on cells. AI action in vitro was assessed
by harvesting experimental medium containing T and 4-AD +/-AI after 24-hour
incubation on cells. Medium harvested was centrifuged at 1000 x g for five minutes at
4°C to pellet floating cells and the supernatant was stored at -80°C prior to analysis.
Experiments were conducted with three technical replicates comprising of medium
harvested from 3-wells of a 6-well plate per treatment, and experiments were conducted
three times independently.

LC-HRMS analysis
Previously validated methods for analysis of estrogens [175] and androgens [173]
from human serum were utilized for analysis of sex steroid metabolism in MCF-7Aro and
LTEDAro culture medium (See Figures 3.1 – 3.3). Androgens were analyzed from 500
µl aliquots of experimental medium with addition of 100 pg heavy-labeled internal
standard prior to liquid-liquid extraction. Internal standard mix for androgen analysis
contained 13C3 T, 13C3 4-AD and D6 DHEA (Cambridge Isotope labs, Tewksbury, MA).
Standard curves were prepared from stock solutions of T, 4-AD, DHEA, epi-testosterone,
and 5α-androstanedione (Steraloids, Newport, RI) in the range of 3.9 – 1000 pg/mL. 50
µL saturated NaCl and 12 µL 1 N HCl were added to medium prior to liquid-liquid
extraction with 2.8 mL methyl-tert-butyl ether (Sigma, St. Louis, MO). The organic
fraction was dried under nitrogen and extracted androgens were derivatized with Girard’s
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reagent P (TCI America, Portland, OR) prior to LC-HRMS analysis. MS analysis was
conducted on a Thermo Q Exactive Plus coupled to an Ultimate 3000 UHPLC interfaced
with a heated electrospray ionization (HESI-II) source following a previously published
method [173].
Estrogens were analyzed from 1 mL aliquots of experimental medium with
addition of 100 pg heavy-labeled internal standard prior to liquid-liquid extraction.
Internal standard mix for estrogen analysis included [13C6]-estradiol and [13C6]-estrone
(Cambridge Isotope labs, Tewksbury, MA). Standard curves were prepared from stock
solutions of unlabeled estradiol and estrone (Steraloids, Newport, RI) in the range of 0.78
– 400 pg/mL. 100 µL saturated NaCl and 20 µL 1 N HCl were added to medium prior to
liquid-liquid extraction with 5 mL diethyl ether (Sigma, St. Louis, MO). The organic
fraction was dried under nitrogen and extracted estrogens were derivatized with 2-fluoro1-methylpyridinium-p-toluenesulfonate (FMP-TS) prior to LC-HRMS analysis (Figure
3.1). Estrogen analysis was conducted on a Thermo Q Exactive HF coupled to an
Ultimate 3000 UHPLC interfaced with a heated electrospray ionization (HESI-II) source.

4-4: Results

Growth response to estrogen vs. androgen precursor in MCF-7Aro and LTEDAro
4-AD and its major metabolite, estrone (0.125-1 nM) induced similar growth responses in
MCF-7Aro cells (Figure 4.1A). T and its main metabolite 17β-estradiol were equipotent
in the range of (0.78 – 50 pM) at inducing growth responses in MCF-7Aro and much
more potent than AD or estrone (Figure 4.1B). Similarly, in LTEDAro cells, 4-AD and
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estrone or T and 17β-estradiol growth responses were equivalent, but there was a much
lower responsiveness to both androgen and estrogen-stimulated growth (Figure 4.1A). A
1.5- and 2-fold increase in growth over vehicle was observed at the highest doses of T or
4-AD in LTEDAro, compared a 4- or 6-fold growth over vehicle observed in MCF-7Aro
at the highest doses T or 4-AD (Figure 4.1A and 4.1B). Androgen-stimulated growth
was completely abrogated by fulvestrant in both LTEDAro and MCF-7Aro (Figures
4.5A and 4.5B).
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Figure 4.1: Proliferation response to estrogen or androgen precursor in MCF7Aro and LTEDAro (A) Growth response to estrone vs. 4-androstenedione in MCF7Aro (ARO) and LTEDAro (LTED). (B) Growth response to estradiol vs. testosterone
in MCF-7Aro and LTEDAro.
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LC-MS reveals complete aromatization of testosterone and 4-androstenedione within 24
hours in MCF-7Aro and LTEDAro

When MCF-7Aro cells were treated with 1 nM 4-AD after three days of growth in
steroid-depleted medium, rapid depletion of 4-AD and rapid formation of estrone was
observed within 4 h. After 16 h, the 4-AD was completely depleted through conversion to
estrone, which was then secreted into the media (220 pg/mL; 0.81 nM) (Figure 4.2A). In
LTEDAro, 4-AD metabolism proceeded more rapidly than in MCF-7Aro, with complete
depletion of 1 nM 4-AD by 4 h coupled with the formation of estrone (244 pg/mL; 0.90
nM) (Figure 4.2B). The maximum level of 4-AD-derived estrone (254 pg/mL; 0.94 nM)
was observed in LTEDAro culture medium at 16 h. Testosterone metabolism also
proceeded more rapidly in LTEDAro compared with MCF-7Aro. In LTEDAro culture
medium, 73% of the T precursor was metabolized within 4 h (Figure 4.2D) compared
with 34% metabolized in MCF-7Aro culture medium at 4 h (Figure 4.2C). In both cell
lines, the maximum T-derived 17β-estradiol levels were observed in the culture media at
24 h when the T precursor was undetectable. The 17β-estradiol levels at 24 h were 235
pg/mL (0.87 nM) for LTEDAro and 210 pg/mL (0.78 nM) for MCF-7Aro (Figures 4.2C
and 4.2D).
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Figure 4.2: Metabolism of estrogen or androgen precursor in MCF-7Aro and
LTEDAro culture medium. (A) Metabolism of 4-androstenedione (4-AD) in MCF7Aro growth medium over 24 hours. (B) 4-AD metabolism in LTEDAro growth
medium over 24 hours. (C) Metabolism of testosterone in MCF-7Aro growth medium
over 24 hours. (D) Metabolism of testosterone in LTEDAro growth medium over 24
hours.
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T and 4-AD metabolism in the presence of third generation AIs in MCF-7Aro and
LTEDAro
The effect of third-generation AIs to suppress estrogen formation from 4-AD and T was
monitored by LC-HRMS. In the absence of an AI, 298 pg/mL estrone (1.1 nM) was
observed in the culture media of MCF-7Aro and LTEDAro cells after a 24-h incubation
with 1 nM 4-AD (Figure 4.3A). After 24 h incubation of cells with 1 nM 4-AD + 1 µM
letrozole, estrone formation was suppressed to < 0.5 pg/mL and 2.3 pg/mL in MCF-7Aro
and LTEDAro, respectively (Figure 4.3A). After 24 h incubation with 4-AD +
anastrozole (1 µM) estrone levels in the media were much higher at 13 pg/mL for MCF7Aro cells and and 33 pg/mL for LTEDAro cells (Figure 4.3A). After incubation of cells
with 4-AD + exemestane (1 µM), estrone levels in the media were 3 pg/mL for MCF7Aro cells and 6.5 pg/mL for LTEDAro cells.
When cells were incubated with a higher concentration of 4-AD (5 nM) in the
absence of an AI, 1631 pg/mL estrone (6.0 nM) was observed in the culture media of
MCF-7Aro and LTEDAro cells after a 24 h incubation (Figure 4.3B). After 24 h
incubation of MCF-7Aro or LTEDAro cells with 5 nM 4-AD + 1 µM letrozole, estrone
formation was suppressed to 4 pg/mL in both cell lines (Figure 4.3B). In the presence of
anastrozole (1 µM), estrone was detectable at 74 pg/mL and 168 pg/mL in in MCF-7Aro
and LTEDAro culture medium, respectively (Figure 4.3B). After incubation of cells with
5 nM 4-AD and exemestane (1 µM), estrone was detectable at 14 and 28 pg/mL MCF7Aro and LTEDAro culture medium, respectively (Figure 4.3B).
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Figure 4.3: Estrogen formation from 4-androstenedione or testosterone substrate in the
presence of AI in MCF-7Aro and LTEDAro. (A) Estrone formation from 1nM 4androstenedione substrate +/- AI at 24 hours in MCF-7Aro(*) or LTEDAro(#) culture medium.
(B) Estrone formation from 5 nM 4-AD +/- AI at 24 hours in MCF-7Aro(*) or LTEDAro(#)
culture medium. (C) Estradiol formation from 1 nM testosterone substrate +/- AI at 24 hours in
MCF-7Aro(*) and LTEDAro(#) culture medium.
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Testosterone metabolism in the presence of AI in MCF-7Aro and LTEDAro is
depicted in Figure 4.3C. In the absence of an AI, 205 pg/mL 17β-estradiol (0.75 nM)
was observed in the culture medium after a 24 h incubation of cells with 1 nM T (Figure
4.3C). In the presence of 1 nM T + 1 µM letrozole, 17β-estradiol levels were suppressed
to < 0.5 pg/mL in culture media of both MCF-7Aro and LTEDAro cells. In the presence
of 1 nM T + 1 µM anastrozole, 17β-estradiol was observed at levels of 1.2 and 2.6 pg/mL
in MCF-7Aro and LTEDAro culture medium, respectively. In the presence of 1 nM T + 1
µM exemestane, 17β-estradiol was observed at levels of 0.8 and 1 pg/mL in MCF-7Aro
and LTEDAro culture medium, respectively.

Androgen levels after AI treatment in vitro
In the absence of an AI, 1 nM 4-AD and T were completely metabolized by both MCF7Aro and LTEDAro cell lines after 24 h (Figure 4.4A and 4.4B). In general, T but not 4AD metabolism was completely inhibited in the presence of AIs. In the presence of any
third-generation AI, only 5-10 % of the T was metabolized in both cell lines (Figure
4.4B) Depletion of 4-AD precursor (1 nM) was observed in the presence of all three AIs
(Figure 4.4A). In the presence of letrozole (1 µM), 12% and 18% of the 4-AD was
metabolized in the MCF-7Aro and LTEDAro cell lines, respectively (Figure 4.4A). In
the presence of anastrozole (1 µM), 25% of the 4-AD was metabolized in both MCF7Aro and LTEDAro cell lines (Figure 4.4A). In the presence of 1 µM exemestane,
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Figure 4.4. 4-androstenedione and testosterone metabolism in the presence of AI in
MCF-7Aro and LTEDAro. (A) Percent of 1 nM 4-androstenedione remaining after 24hour incubation with AI in MCF-7Aro(*) and LTEDAro(#). (B) Percent of 1 nM
testosterone remaining after 24-hour treatment with AI in MCF-7Aro(*) and LTEDAro(#).
(C) Formation of 5a-AD in MCF-7Aro(*) and LTEDAro(#) culture medium after 24-hour
incubation with 1 nM 4-androstenedione +/- AI
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6% and 12% of the 4-AD was metabolized in the MCF-7Aro and LTEDAro cell lines,
respectively (Figure 4.4A). 4- AD (1 nM) was converted to 4 pg/mL 5α-androstanedione
after 24 h in both cell lines in the absence of an AI (Figure 4.4C). In the presence of 1
µM letrozole, anastrozole, or exemestane this increased to an average of 18 pg/mL in the
MCF-7Aro cell line and 34 pg/mL in the LTEDAro cell line (Figure 4.4C).

Androgen-stimulated proliferation in the presence of AI, fulvestrant or combination in
MCF-7Aro and LTEDAro
Proliferation of MCF-7Aro and LTEDAro cells in the presence of AI, fulvestrant or
combination was assessed by XTT assay (Figure 4-5). In MCF-7Aro, androgenstimulated growth (1 nM T or 4-AD) was abrogated by fulvestrant in a dose-dependent
manner (1-32 nM) (Figure 4-5A). In LTEDAro, treatment with fulvestrant decreased
androgen-stimulated growth in the same dose range (1-32 nM) (Figure 4-5B). LTEDAro
cells are cultured under estrogen-deprived conditions and treatment with fulvestrant alone
resulted in inhibition of cell growth to below baseline levels (Figure 4-5B). In MCF7Aro, T-mediated growth was inhibited by AI, but differences in degree of inhibition
among the third-generation AIs were observed (Figure 4-5C). Letrozole exhibited the
greatest potency for inhibiting T-mediated proliferation with an IC50 of approximately 25
nM (Figure 4-5C). Unlike letrozole, neither exemestane nor anastrozole were able to
completely inhibit T-mediated cell proliferation in MCF-7Aro (Figure 4-5C). The
residual growth present after treatment with exemestane or anastrozole was decreased by
fulvestrant in a dose-dependent manner (Figure 4-5D).
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Figure 4.5. Growth inhibition of MCF-7Aro and LTEDAro by AI, fulvestrant or
combination. (A) Growth response to testosterone or 4-androstenedione with increasing dose
fulvestrant in MCF-7Aro. (B) Growth response to androgen + fulvestrant or fulvestrant alone in
LTEDAro. (C) Growth response to 1 nM testosterone with increasing dose AI in MCF-7Aro. (D)
Growth response to 1 nM testosterone, 1 mM AI and increasing dose fulvestrant in MCF-7Aro
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4-5: Discussion
In this study, quantitative analysis of estrogen and androgen formation in the
presence of third generation AIs was undertaken. MCF-7 with aromatase stablyexpressed (MCF-7Aro) and the long-term estrogen deprived LTEDAro cell lines were
used as models of AI responsive vs. resistant breast cancer. Rapid and highly sensitive
LC-HRMS methods were utilized to monitor metabolism of aromatase substrates 4-AD
and T in culture medium, and to quantify levels of estrone, 17β-estradiol and ketoandrogens remaining after treatment with third generation AIs for 24 h. Rapid depletion
of aromatase substrates 4-AD and T corresponded with roughly equimolar formation of
estrone and 17βestradiol in cell culture medium over 24 h in both cell lines (Figure 4-2).
LTEDAro demonstrated an enhanced catalytic activity of aromatase compared with
MCF-7Aro, as evidenced by more rapid formation of estrogens from androgen precursors
after 4 h of incubation on cells (Figure 4-2). Previously, Su et al (2011) reported an
enhanced catalytic activity of aromatase in LTEDAro, which was not explained by
enhanced protein expression, but was potentially caused by post-transcriptional signaling
mechanisms [204]. Rapid 24 h metabolism of 4-AD and T corresponded with
proliferation response, whereby equivalent growth responses were observed to aromatase
substrates and metabolites in both cell lines (Figure 4-1). LTEDAro has a constitutively
active estrogen receptor and demonstrated only 2-fold growth stimulation by androgens
in comparison with up to 6-fold growth stimulation observed in MCF-7Aro when
incubated with the same doses of androgens (Figure 4-1). However, growth response to
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androgen precursor when compared to its relevant estrogen metabolite was equivalent
(Figure 4-1).
Letrozole and exemestane consistently suppressed estrogen formation from
androgen precursors to a greater extent than anastrozole (Figure 4-3). Letrozole was 1030 times more potent than anastrozole at inhibiting estrogen formation in the two cell
lines based on sensitive quantification of estrogen levels remaining, and 2-6 times more
potent than exemestane. The level of suppression of estrogen formation by thirdgeneration AI corresponded with proliferation response in MCF-7Aro, with letrozole
completely suppressing T-mediated growth, while treatment with anastrozole and
exemestane left a 3- or 4-fold residual growth over vehicle at the highest doses of AI
(Figure 4-5C). The fulvestrant-AI combination was found to be effective at inhibiting
residual growth in the presence of higher doses of anastrozole and exemestane (Figure 45D), and fulvestrant inhibited both androgen-stimulated and baseline growth in
LTEDAro (Figure 4-5B). While preclinical studies have demonstrated benefit of AIfulvestrant combination therapy [205, 206], clinical findings are mixed and have not
demonstrated a clear benefit of combining AI with fulvestrant in early or advanced breast
cancer [207]. However, there are indications that use of fulvestrant as a first line of
therapy can result in a significantly longer time-to-progression compared with AI,
particularly anastrozole [208, 209].
Metabolism of 4-AD and T in the presence of AI was assessed in MCF-7Aro and
LTEDAro. While metabolism of T in the presence of AI was found to be less than 10%
of the original precursor, 4-AD continued to be metabolized in the presence of all three
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AI, with the highest percentage of 4-AD metabolism seen in the presence of anastrozole
(Figure 4-4A). This was not necessarily an indication of continued aromatase activity but
could have been due to formation of 4-AD glucuronide or sulfate conjugates or 4-AD
metabolism by other enzymatic pathways. The greater depletion of 4-AD precursor seen
in the presence of anastrozole, however could indicate that some of this is due to
continued aromatization given the differences in potency observed among the three AI
(Figure 4-4A).
In the absence of AI, a low level of 5α-reductase activity was observed in MCF7Aro and LTEDAro as evidenced by formation of 5α-androstanedione (5α-AD) at 4
pg/mL after 24 h incubation of cells with 1 nM 4-AD (Figure 4-4C). In the presence of
AI, higher levels of 5α-AD were detected in both cell lines and were similar among the
three AIs, but approximately two-fold higher in LTEDAro compared with MCF-7Aro
(Figure 4-4C). There is the potential for similar catalysis of testosterone by 5α-reductase
to the potent androgen dihydrotestosterone (DHT), but DHT was not monitored.
Increased expression of 5α-reductase type 2 has been reported after AI therapy in breast
tumors in vivo, with expression of 5α-reductase type 2 and androgen receptor (AR) found
to correlate positively with therapeutic response [210]. In this experimental setting, 5αreductase action on androgens in the presence of an AI could similarly bolster therapeutic
response by enhancing the anti-proliferative action of androgens through the androgen
receptor (AR). However, it is important to note that androgen-mediated action through
AR in breast cancer is context-dependent and not always anti-proliferative [211].

86

The highly sensitivity LC-HRMS method employed in this study has revealed
substantial differences in levels of estrogens present after treatment with third generation
AI in vitro. Substantial differences in potency of aromatase inhibition have been
documented among the third-generation AI currently in use. Studies have consistently
revealed letrozole to have a greater potency than anastrozole for inhibiting aromatase
intracellularly [200], for inhibiting tumor formation in a nude mouse model [202], and for
suppressing serum and tissue estrogen formation in post-menopausal women taking AIs
[80, 193, 194]. However, controversy remains as to whether these differences in AI
potency are relevant with regards to AI therapeutic response and long term success on
adjuvant therapy. Most recently, the FACE trial comparing 5-year disease free survival
and overall survival in women taking letrozole vs. anastrozole did not find a difference in
disease free survival (DFS) or overall survival (OS) between the two drugs [212] among
the entire study population. Importantly, there were differences reported between the
drugs in the sub-group analysis, with letrozole providing greater disease-free survival
among women with later tumor stages (stage 3 or 4) and with Her2+ breast cancer. A
smaller difference was observed in obese women and in women with >4 nodes, with
letrozole trending towards increased disease-free survival in those groups [212].
In 2015, Ingle et al. utilized GC-MS to quantify androgens and estrogens before
AI therapy and at least one month into AI therapy in a cohort of 649 women taking
anastrozole [68]. LC-MS was utilized to confirm that patients were taking anastrozole by
quantifying the parent drug or metabolites from serum. The main finding of the study was
that anastrozole did not suppress estrogen formation in a significant proportion of women
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who were taking the drug. Estrogen levels in women taking anastrozole for at least one
month were found to be as high as 234 pg/mL estradiol and 183 pg/mL estrone. A very
wide baseline range of serum concentrations of 4-AD, T, E1, E2 and E1-conjugate in
women with breast cancer prior to anastrozole therapy was reported. In some women,
serum estrogen levels increased as a result of AI therapy, and androgen levels measured
were mostly unchanged.
There is wide variability in the mechanisms of resistance to AIs and there are also
well-documented differences in potency among third-generation AIs. Therefore, it is
important to identify the subset of women for whom lack of therapeutic response or
recurrence while on AI is being driven by incomplete suppression of serum or tissue
estrogen formation. It has further been demonstrated that the degree of suppression of
estrogen (i.e complete vs. partial) can lead to differences in cellular mechanisms of
resistance to AI [69]. There is a compelling need to more rigorously characterize the
baseline variability of serum androgens in post-menopausal women prior to start of AI
therapy and to monitor the residual levels of both androgens and estrogens. This will
make it possible to better understand the inter-individual variability in response. Rapid
LC-MS assays, such as the LC-HRMS assays employed in the present study, can provide
sensitive and accurate information about the degree to which serum estrogens are
suppressed at the onset of AI therapy, identify non-responders and allow studies
investigating the relationship between level of suppression of serum estrogens and
relapse on adjuvant AI. Application of such assays has the potential to personalize
monitoring of clinical use of AI upon initial treatment and in the adjuvant setting.
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CHAPTER 5: LC-HRMS to trace metabolism of DHEA and DHEA-S at
physiological concentrations in variants of MCF-7

5-1: Abstract
Dehydroepiandrosterone (DHEA) and its sulfate conjugate are present in circulation of
women and men at high concentrations: low nM for DHEA and low µM for DHEA-S.
DHEA and DHEA-S are known to be precursors for peripheral conversion to androgens
and estrogens in post-menopausal women, but the potential role of DHEA or DHEA-S in
stimulating breast cancer growth is unknown. Limited epidemiological evidence exists
suggesting that high levels of circulating DHEA-S can be a risk factor for breast cancer
or for breast cancer recurrence in women treated with endocrine-targeted therapies, but in
vitro investigations into biological response induced by DHEA or DHEA-S in ER+ breast
cancer cells has yielded conflicting results. One complicating factor is the potential for
DHEA to stimulate a biological response through both ER and the androgen receptor
(AR) in breast cancer epithelial cells under different growth conditions. Further, the
importance of formation of downstream androgen vs. estrogen metabolites in breast
cancer cells lines from DHEA precursors is not well understood. Herein, we present an
investigation into biological response and metabolism of DHEA and DHEA-S at
physiological levels in variants of MCF-7, including a model with aromatase-expressed
(MCF-7Aro) and a long-term estrogen deprived model also expressing aromatase
(LTEDAro). Highly sensitive liquid-chromatography - high resolution mass spectrometry
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(LC-HRMS) assays were utilized to quantify androgen and estrogen formation from
physiological levels of DHEA and DHEA-S. We have demonstrated a robust growth
response to DHEA-S in both MCF-7Aro and LTEDAro, which is abrogated by
fulvestrant, and the ability of MCF-7 cells to metabolize DHEA-S to estrogens in the
presence of aromatase. Future directions include assessment of DHEA and DHEA-S
growth response and metabolism in MCF-7 variant cell lines in the presence of aromatase
or sulfatase inhibitors.
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5-2: Introduction

The adrenal steroid DHEA serves as a precursor for peripheral conversion to
downstream androgens and estrogens in men and women. After menopause, the primary
source of estrogens in women is through conversion from androgens of adrenal origin
[47]. Aromatase inhibitors are a primary therapeutic target in post-menopausal estrogen
receptor positive (ER+) breast cancer due to their inhibition of the conversion of C19
androgens (4-androstenedione and testosterone) to C18 estrogens (estrone and estradiol)
systemically and at the site of the tumor [9]. Targeting aromatase in post-menopausal
breast cancer has proven to be a highly effective therapeutic strategy, but development of
resistance is a significant clinical problem [51]. While the majority of research into
mechanisms of resistance to AI has focused on understanding growth factor receptor
cross-talk and constitutive activation of ER which can drive proliferation in what is
considered to be an estrogen-independent manner [59], an important but less discussed
mechanism of resistance is the ability of the breast tumor to modulate its local sex steroid
metabolism when faced with systemic estrogen deprivation to continue to form ER
ligands at the site of the tumor [46, 213].
Alterations in sex steroid metabolizing enzymes have been documented in breast
cancer, including over-expression of steroid sulfatase, aldo-keto reductase 1C3, and
various isoforms of 17β-hydroxysteroid dehydrogenase enzymes, all of which can
modulate the tumors ability to form estradiol locally from steroid conjugates, androgenic
steroids or less potent precursors [37, 41, 43, 44]. However, the mechanisms by which
breast tumors modulate pre-receptor metabolism of estrogens or androgens in direct
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response to AI therapy remains poorly described. Increased expression of steroid
sulfatase and 17β-HSD1 expression was found in women taking the third generation AI
exemestane, which correlated with therapeutic response [45] and altered androgen
metabolism was documented in breast tissue following exemestane treatment [213].
Despite these clinically important observations, understanding about the potential for
tumors to modulate local steroid metabolism in response to systemic estrogen deprivation
is limited.
Serum androgens levels have been found to be potential drivers of breast cancer
risk after menopause [86, 214]. DHEA has been quantified from post-menopausal female
serum at 1-12 nM, and its sulfate conjugate is present in circulation at 1-12 µM [83].
Despite the extremely high levels present in circulation, the potential role of DHEA or its
sulfate conjugate in breast cancer after menopause remains largely unexplored. Limited
epidemiological studies have demonstrated a correlation between DHEA or DHEA-S
levels present in circulation and breast cancer risk [86, 87], while other studies have
found no association [215]. In a small study, DHEA-S levels greater than 90 µg/dl (2.42
µM) were found to correlate with breast cancer progression on AI [89].
With regards to the potential role of circulating DHEA and DHEA-S in postmenopausal breast cancer, several questions can be investigated. Can increased uptake or
metabolism of DHEA or DHEA-S occur in the setting of systemic estrogen deprivation
(i.e. during long-term AI therapy?) Is there any relationship between increased uptake or
metabolism of DHEA or DHEA-S and intrinsic or acquired resistance to endocrine-
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targeted therapies? Does DHEA or DHEA-S require metabolism to estrogens to exert a
biological effect in breast cancer after menopause?
Conflicting reports exist regarding the proliferative vs. anti-proliferative action of
DHEA and DHEA-S in breast cancer. DHEA and DHEA-S have been found to stimulate
proliferation of breast cancer cells in vitro [92, 93, 216-218] and the biological action of
DHEA or DHEA-S has been reported to be mediated through the estrogen receptor [9294, 97, 218] 5-androstenediol (Adiol), a metabolite of DHEA, has also been reported to
be proliferative in breast cancer, with its effects mediated through ER [219, 220]. In
contrast, a few reports exist of DHEA having a growth inhibitory effect in vitro [91] or in
a rodent mammary tumor model [90], and the anti-proliferative action of DHEA has been
reported to be independent of both ER and androgen receptor (AR) [95].
Some discrepancies exist in study design which may account for some of the
differences documented above. When DHEA was administered at pharmacological doses,
the effect was growth-inhibitory [91, 95], but when administered at physiological
concentrations, DHEA stimulated growth of breast cancer cells [92, 93, 95, 216-218] In
steroid-depleted growth medium, DHEA and its metabolite Adiol stimulated growth of
MCF-7 cells, but in the presence of estradiol were found to partially antagonize the
growth-stimulating effect of estradiol [101, 221]. The inhibitory action of DHEA on E2stimulated cell growth in MCF-7 was reported to be through interaction with AR [222].
In cells expressing both ER and AR, DHEA had a proliferative effect which was blocked
by selective estrogen receptor modulator tamoxifen, and in cells expressing only AR,
DHEA had a growth-inhibitory effect which was blocked by the AR antagonist
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bicalutamide [216]. Such context-dependent differences are important to keep in mind
considering that findings of growth-inhibitory action of DHEA have led authors to
recommend administering DHEA as an anti-proliferative agent in breast cancer [91, 95].
Whether DHEA requires metabolism to estrogens to exert a proliferative effect in
breast cancer is not well-clarified. It was reported that cell proliferation and ERα
activation in response to DHEA, Adiol and 4-AD in MCF-7 was enhanced by overexpression of aromatase [99, 223] and that formation of estradiol from 10 nM DHEA was
enhanced by over-expression of aromatase [99]. Schmitt et al. reported formation of 200
pM estradiol in culture medium of parental MCF-7 cells after four day incubation with
100 nM DHEA [100]. In these two reports, estradiol formation was detected using
immunoassay [100] or radioimmunoassay [99], which have problems of specificity, as
previously discussed, and cannot reliably quantify estradiol from biological samples [172,
224, 225]. In contrast, using radiotracer techniques, estrogen formation from 10 µM
DHEA was not observed [92], and a LC-MS method with adequate sensitivity to detect
estrone formation but not estradiol also did not observe formation of estrogen from 100
nM DHEA precursor [181]. In another report, metabolism of DHEA and DHEA-S was
traced at physiological concentrations in MCF-7 by LC-MS, and the authors reported
formation, but not quantification of downstream estrogen metabolites from 1 µM DHEAS, but not 10 nM DHEA [98]. Alternately, studies have reported formation of Adiol from
DHEA by breast cancer cells, which subsequently stimulates proliferation through ER
[218, 219, 226]. Overall, studies investigating metabolism of DHEA or DHEA-S in vitro
have been conducted using immunoassays, MS but not quantification, or MS methods
94

lacking sensitivity to detect low-level estrogen formation from DHEA precursors.
Therefore, the question of whether and to what extent breast cancer cells metabolize
DHEA and DHEA-S to downstream androgens or estrogens, and whether aromatase
plays a significant role in the proliferative effect of DHEA to date remains unclarified.
Additionally, it is not clear whether conversion to a5-androstenediol and subsequent
direct action through ER or metabolism of DHEA to estrogens plays a more significant
role in breast cancer cells and in post-menopausal breast cancer.
The purpose of this study is to examine proliferation response and metabolism of
physiological levels of DHEA and DHEA-S to androgens and estrogens in MCF-7 and
variants. Cell lines included in the study are MCF-7, MCF-7 with aromatase overexpressed (MCF-7Aro [178]) and a long-term estrogen deprived cell line formed from
long-term growth of MCF-7Aro in the absence of estrogens (LTEDAro [179]). LTEDAro
has the capacity to proliferate in the total absence of estrogens, and also demonstrates
hypersensitivity to growth stimulation by E2. The purpose of including these three cell
lines is to test whether differences in proliferation response and metabolism to DHEA or
DHEA-S at physiological concentrations can be observed in the presence or absence of
aromatase (MCF-7 vs. MCF-7Aro), and in a cell line which has adapted to growth in the
absence of E2 and is a model for the transition to endocrine therapy resistance
(LTEDAro). Highly sensitive and specific LC-HRMS methods were applied to trace
metabolism of DHEA (10 nM and 100 nM) and DHEA-S (1 µM) to keto-androgens and
estrone and estradiol. Future analysis includes quantification of Adiol formation from
DHEA and DHEA-S in variants of MCF-7 [227].
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5-3: Materials and methods
Cell culture
MCF-7 cells were obtained from ATCC (Manassas, VA). MCF-7Aro and LTED-Aro
cells were obtained from Dr. Shiuan Chen City of Hope, Duarte, CA. MCF-7 and MCFAro cells were cultured in phenol-red free RPMI 1640 medium (Invivogen, San Diego,
CA) containing 10% fetal bovine serum with 100 µg/mL primocin as an antimicrobial
agent (Invivogen, San Diego, CA). LTED-Aro cells were cultured in phenol-red free
RPMI 1640 medium containing 10% double charcoal-dextran stripped fetal bovine serum
(CS FBS) (Gemini Bioproducts, West Sacramento, CA) and 100 µg/mL primocin.
Proliferation assays
Cell proliferation was assessed using the XTT cell proliferation assay kit (ATCC,
Manassas, VA). MCF-7Aro cells were diluted to a final concentration of 7810 cells/mL
and 100 µL cell suspension was added per well of a 96-well plate. Cells were allowed to
grow for three days in serum-deprived conditions (RPMI 1640 medium containing 10%
CS FBS) prior to addition of experimental medium. Upon addition of experimental
medium, cells grew for an additional 10 days prior to taking absorbance readings at 475
nm and 660 nm according to manufacturer’s recommendations. LTEDAro cells were
diluted to a final concentration of 4x103 cells/mL in RPMI 1640 containing 10% CS FBS,
and 100 µL cell suspension was added per well of a 96-well plate. Cells were allowed to
grow for two days prior to addition of experimental medium, and then grew an additional
10 days prior to analysis. Experiments were conducted in biological triplicate with
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similar results. Proliferation in response to the following compounds was assessed: 50
pM estradiol; 10 nM DHEA; 100 nM DHEA; 1 µM DHEA, 1 µM DHEA-S, 5 µM
DHEA, 5 µM DHEA-S; 1 or 5 µM DHEA + 30 nM fulvestrant, and 1 or 5 µM DHEA-S
+ 30 nM fulvestrant. Vehicle for all experiments was DMSO at a final concentration of
0.01%.
Cellular metabolism of DHEA and DHEA-S
MCF-7 cells or variant cell lines were plated in 6-well plates in steroid-depleted
conditions (RPMI 1640 medium containing 10% CS FBS) and allowed to grow for three
days prior to addition of experimental medium. MCF-7 cells were plated at a 5x105
cells/well of a 6-well plate; MCF-7Aro cells were plated at 4x105 cells/well of a 6-well
plate; and LTEDAro cells were plated at a density of 2.5x105 cells/well of a 6-well plate.
Experimental medium formulations were made by adding individual steroids or steroidinhibitor combination to RPMI 1640 containing 10% CS FBS. Vehicle for all
experiments was DMSO at a final concentration of 0.01%. Background sex steroid levels
in CS FBS were assessed by quantifying a panel of estrogens and androgens by LC-MS.
All compounds were undetectable in undiluted CS FBS, making RPMI containing 10%
CS FBS a suitable matrix for assessment of individual sex steroid metabolism in MCF-7
and variant cell lines. Metabolism of the following compounds was assessed in three cell
lines: 10 nM DHEA; 100 nM DHEA and 1 µM DHEA-S. A time-course of DHEA
metabolism was assessed by harvesting experimental medium after a 2-hour, 16-hour, 24hour and 48-hour incubation on cells. Medium harvested was centrifuged at 1000 x g for
five minutes at 4°C to pellet floating cells and the supernatant was stored at -80°C prior
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to analysis. Experiments were conducted with three technical replicates comprising of
medium harvested from 3-wells of a 6-well plate per treatment, and experiments were
conducted three times independently.
LC-HRMS analysis
Previously reported LC-HRMS methods [173] or LC-MS/MS methods adapted to a LCHRMS platform [175] were utilized for analysis of sex steroid metabolism formed in
MCF-7Aro and LTEDAro culture medium. Androgens were analyzed from 500 µl
aliquots of experimental medium with addition of 100 pg heavy-labeled internal standard
prior to liquid-liquid extraction. Internal standard mix for androgen analysis contained
13

C3 T, 13C3 4-AD and D6 DHEA (Cambridge Isotope labs, Tewksbury, MA). Standard

curves were prepared from stock solutions of T, 4-AD, DHEA, epi-testosterone, and 5αandrostanedione (Steraloids, Newport, RI) in the range of 3.9 – 1000 pg/mL. 50 µL
saturated NaCl and 12 µL 1 N HCl were added to medium prior to liquid-liquid
extraction with 2.8 mL methyl-tert-butyl ether (Sigma, St. Louis, MO). The organic
fraction was dried under nitrogen and extracted androgens were derivatized with Girard’s
reagent P (TCI America, Portland, OR) prior to LC-HRMS analysis. HRMS analysis was
conducted on a Thermo Q Exactive Plus coupled to an Ultimate 3000 UHPLC interfaced
with a heated electrospray ionization (HESI-II) source following a previously published
method [173].
Estrogens were analyzed from 1 mL aliquots of experimental medium with
addition of 100 pg heavy-labeled internal standard prior to liquid-liquid extraction.
Internal standard mix for estrogen analysis included [13C6]-estradiol and [13C6]-estrone
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(Cambridge Isotope labs, Tewksbury, MA). Standard curves were prepared from stock
solutions of unlabeled estradiol and estrone (Steraloids, Newport, RI) in the range of 0.78
– 400 pg/mL. 100 µL saturated NaCl and 20 µL 1 N HCl were added to medium prior to
liquid-liquid extraction with 5 mL diethyl ether (Sigma, St. Louis, MO). The organic
fraction was dried under nitrogen and extracted estrogens were derivatized with 2-fluoro1-methylpyridinium-p-toluenesulfonate (FMP-TS) prior to LC-HRMS analysis. Estrogen
analysis was conducted on a Thermo Q Exactive HF coupled to an Ultimate 3000
UHPLC interfaced with a heated electrospray ionization (HESI-II) source as described in
Chapter 3.

5-4: Results
Proliferation response to DHEA-S in variants of MCF-7
Both MCF-7Aro and LTEDAro exhibit a strong proliferative response to
physiological levels of DHEA-S with growth curves in the range of 30 nM – 1 µM
DHEA-S in MCF-7Aro and 156 nM – 5 µM in LTEDAro (Figure 5.1). MCF-7Aro
exhibits an equivalent growth response when cells are dosed with 1 µM unconjugated
DHEA or 1 µM DHEA-S (Figure 5.1A), though levels of unconjugated DHEA generally
would not surpass 10 nM in vivo. Equivalent growth responses to 5 µM DHEA and 5 µM
DHEA-S are similarly observed in LTEDAro (Figure 5.1B). Fulvestrant completely
abrogates DHEA-S stimulated growth in MCF-7Aro and LTEDAro at a concentration of
32 nM both MCF-7Aro and LTEDAro (Figure 5.1A and 5.1B). In MCF-7Aro, the
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A.

B.

Figure 5.1. DHEA-S growth response in variants of MCF-7. A. 10-day
proliferation response to 0.03 – 1 µM DHEA-S and controls in MCF-7Aro; B.
10-day proliferation response to 0.16 – 5 µM DHEA-S and controls in LTEDAro
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maximal growth response to DHEA-S was 90% of that stimulated by 50 pM E2, a
strongly proliferative dose in MCF-7Aro (Figure 5.1A). In LTEDAro, the maximal
growth response to DHEA-S was 107% of that stimulated by the maximally proliferative
dose of E2 (Figure 5.1B). LTEDAro exhibits hypersensitivity to growth in estradiol, and
maximal proliferation to E2 was observed at 6.25 pM . 10 nM DHEA did not stimulate
proliferation in either MCF-7Aro or LTEDAro.

DHEA metabolism in variants of MCF-7
DHEA consumption was analyzed in culture medium of MCF-7 and variants by
LC-HRMS after organic extraction and GP derivatization (Figure 5.2). Precursor
depletion ranged from 10% – 39% across the three cell lines (Figure 5.2). In MCF-7Aro,
10% of the original DHEA precursor at 10 nM or 100 nM was consumed by 48 hours
(Figure 5.2A and 5.2B). In LTEDAro, an average of 36.5% of the original precursor was
consumed by 48 hours (39% of 10 nM DHEA and 34% of 100 nM DHEA) (Figure 5.2A
and 5.2B). In MCF-7, 25% of 10 or 100 nM DHEA precursor was consumed by 48 hours
(Figure 5.2A and 5.2B).
DHEA formation from 1 µM DHEA-S over 48 hours was traced in MCF-7 and
variants (Figure 5.2C). After 48 hours, DHEA was quantified from culture medium at
the following levels: 646 pg/mL (1.8 nM) in MCF-7Aro, 649 pg/mL (1.8 nM) in
LTEDAro and 973 pg/mL (2.6 nM) in parental MCF-7 (Figure 5.2C). Sulfatase activity
was found to be higher in MCF-7 than in the MCF-7Aro and LTEDAro variants, but was
low for all three.
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Figure 5.2. DHEA or DHEA-S consumption in variants of MCF-7. Androgens were
extracted from 0.5 mL culture medium and analyzed as GP-derivatives by LC-HRMS. A:
Consumption of 10 nM DHEA after 24- and 48-hour incubation on MCF-7, MCF-7Aro and
LTEDAro cells. B: Consumption of 100 nM DHEA after 24- and 48-hour incubation on three
cell lines. C: DHEA formation from 1 µM DHEA-S in culture medium of three cell lines at 24
and 48 hours
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Formation of a panel of keto-androgens as well as estrone and estradiol was
assessed from 10 nM DHEA, 100 nM DHEA or 1 µM DHEA-S using LC-HRMS
(Figure 5.3). In parental MCF-7, DHEA metabolism resulted in formation of 4androstenedione at 81 pg/mL from 10 nM DHEA, 384 pg/mL from 100 nM DHEA and
26 pg/mL from 1 µM DHEA-S (Figure 5.3A). No downstream formation of estrogens
was observed in culture medium of MCF-7 (Figure 5.3A). In MCF-7Aro, formation of
testosterone from DHEA or DHEA-S was observed at the following levels: 16 pg/mL
from 10 nM DHEA, 43 pg/mL from 100 nM DHEA and 641 pg/mL from 1 µM DHEA-S
(Figure 5.3B). Formation of estrone was quantified at 10 and 67 pg/mL from 10 and 100
nM DHEA, and at 4.7 pg/mL from 1 µM DHEA-S. Estradiol was quantified from MCF7Aro culture medium at 2.6 pg/mL after 48 hour incubation with 100 nM DHEA, and 4.9
pg/mL after 48 hour incubation with 1 µM DHEA-S (Figure 5.3B). In LTEDAro,
androgen formation was not observed from DHEA or DHEA-S precursors, and estrone
and estradiol formation was at similar levels as those seen in MCF-7Aro. Estrone was
quantified from culture medium of LTEDAro at the following levels after 48 hour
incubation with DHEA or DHEA-S: 10 pg/mL after 48 hour incubation with 10 nM
DHEA, 37 pg/mL after 48 hour incubation with 100 nM DHEA and 74 pg/mL after 48
hour incubation with 1 µM DHEA-S (Figure 5.3C). Estradiol was not detected after 48
hour incubation with 10 nM DHEA, but was quantified from LTEDAro culture medium
at 2.6 pg/mL after incubation with 100 nM DHEA and 4.9 pg/mL after incubation with 1
µM DHEA-S (Figure 5.3 C).
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B.

C.

Figure 5.3. Androgen and estrogen formation from DHEA or DHEA-S at physiological
levels in variants of MCF-7. A: Metabolites formed in culture medium of MCF-7 after 48-hour
incubation with DHEA (10, 100 nM) or DHEA-S (1 µM). B: Metabolites formed in culture
medium of MCF-7Aro after 48-hour incubation with DHEA or DHEA-S at the same
concentrations as in (A). C: Metabolites formed in culture medium of LTEDAro after 48-hour
incubation under the same conditions as (A) and (B).

104

5-5: Discussion
The purpose of this study was to investigate metabolism of DHEA and its sulfate
conjugate, DHEA-S, in vitro models of post-menopausal breast cancer, particularly to
assess the role of aromatase in the metabolism of DHEA or DHEA-S to estrogens.
Proliferation response and metabolism was assessed in variants of MCF-7 +/- aromatase,
(MCF-7 vs. MCF-7Aro) and in a cell model of endocrine therapy-resistant breast cancer
(LTEDAro). Both MCF-7Aro and LTEDAro exhibited a strong proliferative response to
physiological concentrations of DHEA-S (1 or 5 µM) which was completely suppressed
by fulvestrant, indicating an ER-dependent mechanism (Figure 5.1). Growth
responsiveness of parental MCF-7 to DHEA-S has been previously reported, and will be
repeated in conjunction with these experiments in order to more directly compare growth
response among the parental vs. variant cell lines.
Differences in downstream metabolism of DHEA and DHEA-S were found
among the variant MCF-7 cell lines. Most notably, the ability to form estrogens from
DHEA-S was only demonstrated in the presence of aromatase (Figure 5.3). In parental
MCF-7, 4-AD formation was detected after incubation with DHEA or DHEA-S, but in
the absence of aromatase no subsequent metabolism of 4-AD precursor to estrogens was
detected (Figure 5.3A). In the variant cell lines expressing aromatase, estrogen formation
was detected from all precursors tested (10 and 100 nM DHEA and 1 µM DHEA-S)
(Figure 5.3B and 5.3C). LTEDAro formed a high level of estrone (74 pg/mL) after
incubation with DHEA-S while MCF-7Aro formed a high level of testosterone (640
pg/mL) (Figure 5.3 B and 5.3C). In both cell lines, a very low pM level of estradiol was
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formed after 48-hour incubation with 1 µM DHEA-S, 2.9 pM in MCF-7Aro and 1.3 pM
in LTEDAro (Figure 5.3 B and 5.3C).
It is interesting to consider these results in light of some of the discrepancies
present in the literature regarding DHEA metabolism. For example, Schmitt et al.
reported formation of 200 pM estradiol in MCF-7 growth medium after 4-day incubation
with 100 nM DHEA, with estradiol levels assessed by immunoassay [100]. In contrast,
Poescher et al. did not find any estrogen formation from 100 nM DHEA in the same cell
line using LC-MS techniques, though the method did not have sensitivity to detect low
level estradiol formation (limit of quantification for estradiol was 140 pg/mL) [181]. In
our study, no estrogen formation was observed in MCF-7 from 100 nM DHEA precursor,
and in the presence of aromatase estrone was detected at a level of 67 pg/mL in MCF7Aro and 37 pg/mL in LTEDAro, as well as formation of 4 and 2.6 pg/mL estradiol in
these cell lines, respectively (Figure 5.3). Maggiolini et al. reported formation of
estradiol as detected by radioimmunoassay from 10 nM DHEA in both parental MCF-7
and in an aromatase-overexpression model in MCF-7, reporting a 9-fold vs. a 14-fold
increase of E2 levels over baseline in these two cell lines after incubation with 10 nM
DHEA [99]. In contrast, metabolism of 10 nM DHEA was assessed in this study in MCF7 as well as two cell models which over-express aromatase and no estradiol formation
was observed after 48-hour incubation with 10 nM DHEA in any cell line. These results
demonstrate the necessity of utilizing MS-based quantitative methods that have the
sensitivity and specificity to come to accurate conclusions regarding the metabolism of
adrenal steroids at physiological levels.
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Is the biological response induced by DHEA-S in MCF-7Aro and LTEDAro
related to this low level of estrogen formation? Alternate views will be discussed. On
the one hand, metabolism of DHEA-S to estrogens at the site of the breast tumor may
represent an alternate source of estrogens beyond those formed from circulating T, 4-AD
or estrogen-sulfates. It has been demonstrated that breast cancer cells grown long-term in
very low pM concentrations of estradiol develop cellular resistance mechanisms that are
distinct from breast cancer cells grown long-term in the total absence of estradiol [228].
Long-term estrogen deprivation can also stimulate hypersensitivity to growth induced by
estradiol [229]. Metabolism of DHEA-S to very low levels of estradiol in the LTEDAro
model in particular has the potential to significantly influence cell growth. It should be
noted that DHEA-S concentrations in post-menopausal women can far exceed 1 µM,
therefore it’s possible that higher levels of estrogens would be formed in the presence of
aromatase in women with endogenously high DHEA-S levels [86, 87, 89] and see
Chapter 6, Figure 6.4. Since this low-level estrogen formation was observed only in the
presence of aromatase in MCF-7, the effect of aromatase inhibitors on DHEA-S
metabolism and growth response in these in vitro cell models warrants further
investigation.
An alternate view of the relevance of estrogen formation in these cell models is
also possible. There have been reports of DHEA metabolism to low nM levels of Adiol in
breast cancer cell lines [92, 219] and that such Adiol concentrations can strongly induce
proliferation by directly binding ER [218, 219]. As robust proliferation responses to
DHEA-S have been reported in MCF-7, and now in MCF-7Aro and LTEDAro, it is
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plausible that the biological response of breast cancer cells to DHEA-S is not due to
estrogen formation, but due to metabolism of DHEA or DHEA-S to Adiol and
subsequent direct action through ER. It is not clear that the low pM level of estrogens
quantified after 48 hour incubation of MCF-7Aro and LTEDAro are adequate to explain
the robust proliferation response seen in response to DHEA-S, which is comparable to the
maximal proliferation stimulated by 50 pM E2 in MCF-7Aro, and 6.25 pM E2 in
LTEDAro, which exhibits hypersensitivity to growth stimulation by E2. There is some
difficulty in making this comparison, as 48-hour metabolism was assessed by MS but
evaluating proliferation response requires 10 days of growth in various steroid precursors
in order to generate definitive results.
The potential for MCF-7 cells to metabolize DHEA or DHEA-S to Adiol and
subsequently drive proliferation through ER is a potential pathway of ligand-dependent
activation of ER which would be completely outside of the aromatase pathway for
formation of ER agonists, and would not be affected by inhibition of aromatase. Indeed,
the conversion of DHEA to Adiol is catalyzed by 17β-HSD enzymes or AKR1C3 (See
Figure 1.2), and isoforms of 17β-HSD as well as AKR1C3 have been found to be
overexpressed in breast cancer [41, 43, 44]. It has been further demonstrated that steroid
sulfatase and 17β-HSD expression can be modulated in women taking AI [45]. Therefore,
it is plausible that changes in the expression level of steroid sulfatase, 17β-HSD enzymes
or AKR1C3 could represent an adaptive intracrine change allowing breast tumors to
increase local formation of Adiol from DHEA or DHEA-S at concentrations sufficient to
strongly drive proliferation through ER. Therefore, assessing Adiol formation from
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DHEA or DHEA-S in the current MCF-7 variants would be very informative, as well as
expanding the current study to include MCF-7 with AKR1C3 stably expressed [44]. A
pro-estrogenic state has previously been demonstrated in this cell line [44], and it would
be useful to investigate the potential role of AKR1C3 expression in modulating the
response of breast cancer cells to DHEA-S.
Future avenues for study include assessment of DHEA-S metabolism and growth
response in the presence of AI and sulfatase inhibitors, and also in an AKR1C3 overexpression cell model. Exploring the clinical relevance of either estrogen or Adiol
formation from DHEA-S should include an assessment of the role of fulvestrant in
managing ER+ breast cancer after menopause, as this drug has the potential to interrupt
the ligand-dependent ER activation stimulated by either estrogens or Adiol.
In conclusion, in this study highly sensitive LC-HRMS assays have been applied
for robust quantification of DHEA and DHEA-S to downstream estrogen and androgen
metabolites in variants of MCF-7. These assays enabled quantification of trace levels of
estrogens formed from DHEA or DHEA-S precursors in the presence of aromatase. This
study represents an advance over previous studies assessing DHEA or DHEA-S
metabolism in MCF-7 as previous studies have assessed metabolism of DHEA precursors
at levels higher than physiological range [91], without quantification [98] or without the
required sensitivity [181] or specificity [99] to quantify low level estrogen formation
from DHEA precursors. In Chapter 6, I will present results from a small clinical study in
which DHEA and DHEA-S was quantified from serum of women on adjuvant AI who
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progressed to metastatic breast cancer to present the variability of serum DHEA and
DHEA-S levels found in this population (Figure 6-4).
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CHAPTER 6: Comprehensive serum steroid hormone measurements in the prelude
to metastatic breast cancer

6-1: Abstract
Despite improved efficacy over tamoxifen demonstrated by third-generation aromatase
inhibitors (AI) in combatting ER+ breast cancer, women taking AI continue to be at risk
for relapse up to 15 years after initial diagnosis. Extensive research has been conducted to
understand mechanisms of resistance in ER+ breast cancer that develop when tumors
adapt to growth in the total absence of estrogens. Such models assume that complete
estrogen suppression is achieved and sustained in a vast majority of women on AI. In
fact, the biological variability of serum estrogen and androgen levels in women before
and during AI therapy is not well-defined because of a reliance on methods that lack the
specificity to provide accurate sex steroid measurements. MS-based methodologies offer
a significant advance in sensitivity and specificity for reliable quantification of estrogens
and androgen at the low levels present in post-menopausal female serum and in women
on AI. Application of such assays will allow for clinical and epidemiological studies to
be conducted to assess the relationship between sub-optimal estrogen suppression by AI
and disease outcomes. The Wellness After Breast Cancer (WABC) cohort study was
formed to assess biological determinants of symptom distress and disease outcomes in
women on adjuvant AI. In this report, comprehensive serum estrogen and androgen
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measurements were made in 23 cohort women who progressed to metastatic disease. All
but five women were taking AI at the time of serum collection, yet significant serum
concentrations of estrogen metabolites were detectable in this analysis. This report
represents an exploratory analysis prior to expansion to a nested case-control study within
the WABC cohort comparing serum profiles of estrogens and androgens among women
who relapse vs. those who do not.
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6-2: Introduction

Elevated levels of androgens have been found to be a risk factor for breast cancer
[81, 86]. However, studies assessing breast cancer risk have frequently employed use of
immunoassays, which have well-established problems of specificity [73]. Therefore, the
true extent of the relationship between circulating androgen levels with breast cancer risk
is not well-characterized because it has not been investigated using consistent or reliable
quantitative methods. Understanding variability of AI response in post-menopausal
women has suffered the same methodological limitations. LC-MS/MS or LC-HRMS
offers a significant advance in sensitivity and specificity for reliable quantification of
estrogens and androgen at levels present in post-menopausal female serum and in women
on AI.
Recently, epidemiological studies have begun to investigate the relationship
between circulating estrogen levels and breast cancer risk using LC-MS/MS
methodologies [230]. However, there has been no analogous application of MS-based
methodologies to investigate differences in degree of estrogen suppression among women
taking third generation AI. Application of such assays to reliably quantify estrogens and
androgens from post-menopausal female serum has the capacity to greatly enhance
understanding of baseline biological variability in this population, to help clarify the
relationship between circulating estrogens and androgens and breast cancer risk, to
increase understanding of differences in degree of systemic estrogen suppression in
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women taking AI and to allow for systemic exploration of the relationship between
degree of estrogen suppression in women on adjuvant AI and risk for relapse.
Preclinical and small clinical studies have pointed to differences in potency
among commonly used23 AI [68, 80, 193, 194] but the relationship between inadequate
estrogen suppression at the onset of therapy or in the adjuvant setting and disease
outcomes has never been systemically explored. In 1996, Lønning et al. investigated the
relationship between plasma estrogen levels on disease-free interval (time from first
breast cancer diagnosis to relapse) in post-menopausal women treated for breast cancer
and found an association with serum estradiol and estrone-sulfate and development of
micrometastases [197]. In another study, serum profiles of a panel of androgens plus
estradiol was assessed by radioimmunoassay, and levels compared between women
taking AI as a second line of therapy vs. women adjuvant AI. This study reported
significantly higher serum 4-AD and estradiol in the cohort of women with AI as the
second line of therapy, but warrants repeating with more reliable methods [231].
The Letrozole (Femara) vs Anastrozole Clinical Evaluation study (FACE) was
designed to compare whether the differences in potency that have been reported between
letrozole and anastrozole would be related to risk of relapse within 5 years in women
with node-positive disease [212]. No difference was found among all study participants
for disease-free survival and overall survival between the two drugs after 5 years.
However, the subgroup analysis revealed difference in disease-free survival (DFS) in
women with tumor stage >III (hazard ratio 0.77 (0.53 – 1.12) and with Her2+ breast
cancer (hazard ratio 0.69 (0.45 – 1.06), with letrozole demonstrating better 5-year DFS
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for both of these sub-groups. There was also a smaller trend in obese women (hazard
ratio 0.86 (0.54 – 1.37) and in women with >4 nodes (hazard ratio 0.86 (0.69 – 1.06)
demonstrating slightly increase in DFS in women treated with letrozole. Anastrozole
demonstrated better DFS in women with early breast cancer (tumor stage T0 or T1;
hazard ratio 1.23 (0.93 – 1.62) and the benefit for letrozole increased with tumor stage
[212]. In another study, efficacy of letrozole vs. anastrozole was compared in women
with advanced breast cancer who had progressed on tamoxifen, and a significantly better
overall response rate was observed with letrozole, but no differences in disease-free
survival or overall survival were found [232].
The largest study to date to apply MS-based methods for quantification of serum
estrogens and androgens in women on AI therapy was reported in 2015 [68]. As
discussed in Chapter 4, this study quantified E1, E2, estrone conjugates and androgen
precursors and found that estrogens were not suppressed in a substantial proportion of
women taking anastrozole and in some cases serum estrogen levels increased at onset of
treatment.
Systematic exploration of estrogen and androgen levels in women who relapse vs.
those who do not offers the potential to investigate whether long-term sub-optimal
estrogen suppression in the adjuvant setting is associated with increased risk for relapse.
The Wellness After Breast Cancer Cohort Study II (WABC II), co-directed by Dr.
Angela DeMichele (Division of Hematology and Oncology, Perelman Center for
Advanced Medicine, Philadelphia, PA) and Dr. Jun Mao (Memorial Sloan Kettering
Cancer Center, New York, NY) follows a cohort of 1700 women on adjuvant AI
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followed long-term after breast cancer. This study is an extension of the original WABC I
cohort which enrolled 500 women. The purpose of this clinical study is to identify
biological determinants of symptom distress and disease outcomes among women taking
adjuvant AI.
From this study, a quantitative analysis of serum estrogen and androgen levels in
serum of 23 women who progressed to metastatic disease has been conducted, including
quantification of a panel of estrogen metabolites, androgen precursors and DHEA-S. This
was an exploratory analysis to quantify estrogen and androgen levels in a small subset of
women in the cohort before expanding to larger studies. All samples were harvested at
time of enrollment in the WABC cohort study, and of the 23 women who relapsed, 18
were reported to be on AI at the time of entry into the WABC II cohort, four had
progressed on AI and were being treated with chemotherapy or other endocrine therapies,
and one had discontinued AI due to bone loss. In this chapter, I present LC-HRMS
analysis of a panel of estrogens and androgens from serum of 23 women on adjuvant AI
who all progressed to metastatic breast cancer. Current work is aimed at expanding this
current analysis to a nested case-control study of relapsers vs. non-relapsers within the
WABC II cohort (n=198).
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6-3: Materials and methods

Sample information:
Serum from 23 women on adjuvant AI was obtained from co-directors of the
WABC-II study Dr. Angela DeMichele and Dr. Jun Mao. All women in this analysis
progressed to metastatic breast cancer. Samples were collected at time of entry into the
study, which in some cases was prior to relapse. Samples were de-identified prior to
analysis in the Blair lab, and relapse status was not known until after completion of LCHRMS analysis. Women had given permission at the time of entry into the study for
multiple biochemical analysis of serum samples as deemed necessary by the study
investigators. Thus, new permission was not required or obtained for this additional
analysis.
Estrogen quantification:
For quantification of total serum estrogens, 100 µl aliquots of human serum were
incubated with β-glucuronidase/arylsulfatase from Helix pomatia (Roche, Indianapolis,
IN) prior to extraction and analysis by LC-HRMS. An internal standard mix containing
isotopically-labeled standards corresponding to the analytes of interest was added to
serum prior to hydrolysis. For analysis of a panel of twelve estrogen metabolites, internal
standard mix contained [13C6]-estrone, [13C6]-estradiol, [13C3]-16α-hydroxy-estrone,
[13C3]-estriol, [13C6]-2-hydroxy-estrone, [13C6]-4-hydroxy-estrone, [13C6]-2-methoxyestrone, [13C6]-4-methoxy-estrone, [13C6]-2-hydroxy-estradiol, [13C6]-2-methoxyestradiol, [13C6]-4-methoxy-estradiol (Cambridge Isotope labs, Tewksbury, MA) and
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[2H5]-4-hydroxy-estradiol (CDN Isotopes, Pointe-Claire, Quebec, Canada). Off the clot
double charcoal-stripped human serum (Golden West Biologicals, Temecula, CA) was
used as an analytical matrix for quantification of estrogen metabolites from human
serum. Standard curves in the range of 0.125 – 400 pg/mL were prepared from stock
solutions of a panel of twelve estrogen metabolites in methanol: estrone, estradiol, 16αhydroxy-estrone, estriol, 2-hydroxy-estrone, 4-hydroxy-estrone, 2-methoxy-estrone, 4methoxy-estrone, 2-hydroxy-estradiol, 4-hydroxy-estradiol, 2-methoxy-estradiol and 4methoxy-estradiol (Steraloids, Newport, RI).
The hydrolysis reaction was prepared as follows. 100 pg internal standard mix in
10 µl methanol was spiked into 100 µl human serum, followed by 100 µl water, 100 µl
0.5% L-ascorbic acid, 200 µl sodium acetate buffer (200 mM, pH 5.0), and 10 µl βglucuronidase/ arylsulfatase. Samples were incubated at 37°C for 19 hours. After
hydrolysis, samples were acidified with 10 µl 1N HCl and 50 µl saturated sodium
chloride was added. Samples underwent liquid-liquid extraction (LLE) with 1.5 mL
methyl-tert-butyl ether (Sigma, St. Louis, MO) by shaking on a multi-vortexer for 10
minutes, followed by centrifugation at 3600xg for 15 minutes. The upper, organic layer
containing extracted total estrogens was removed and dried under nitrogen prior to
chemical derivatization with pyridine-3-sulfonyl chloride as previously described [176].
Targeted / untargeted analysis was conducted on a Thermo Q Exactive HF coupled to an
Ultimate 3000 UHPLC interfaced with a heated electrospray ionization (HESI-II) source
as an adaptation of methods described in [176] to a LC-HRMS platform.
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Keto-steroid quantification:
Keto-steroids were analyzed from 100 µl human serum as unconjugated steroids,
no hydrolysis step was included for this analysis. An internal standard mix containing
isotopically-labeled standards corresponding to analytes of interest was spiked into serum
prior to LLE. Internal standard mix contained [13C3]-testosterone, [13C3]-4androstenedione, [2H6]-dehydroepiandrosterone, and [13C6]-estrone (Cambridge Isotope
labs, Tewksbury, MA). Off the clot double charcoal-stripped human serum (Golden West
Biologicals, Temecula, CA) was used as an analytical matrix for quantification of ketoandrogen metabolites from human serum. Calibration curves were prepared from stock
solutions of keto-steroids in the following ranges: testosterone, 5α-androstanedione, epitestosterone, 4-androstenedione and estrone at 3.9 – 1000 pg/mL, and
dehydroepiandrosterone at 19.5 – 5000 pg/mL. Keto-androgens and estrone present in
100 µl human serum underwent liquid-liquid extraction with 2.5 mL methyl-tert-butyl
ether (Sigma, St. Louis, MO) after addition of 300 µl water, 100 µl saturated NaCl and 10
µl 1N HCl. Samples were vortexed on a multi-vortexer for 10 minutes and then
centrifuged for 15 minutes at 3600xg. The upper, organic layer containing extracted ketosteroids was removed and dried under nitrogen prior to chemical derivatization with
Girard’s reagent P and LC-HRMS analysis. Analysis was conducted on a Thermo Q
Exactive Plus coupled to an Ultimate 3000 UHPLC interfaced with a heated electrospray
ionization (HESI-II) source as previously described [173].
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Direct quantification of DHEA-S:
DHEA-S was quantified from 10 µL aliquots of human serum after addition of 1
ng [2H5]-DHEA-S internal standard. Samples were diluted were diluted with 90 µL water
and cleaned with a methanol-chloroform extraction as well as SPE using Oasis HLB
cartidges (Waters Corporation, Milford, MA) prior to injection onto the LC column. A
standard curve was prepared from a stock solution of DHEA-S (Steraloids, Newport, RI)
in the range of 1 – 20 µM. DHEA-S was quantified as an intact sulfate conjugate in
negative ion mode by LC-HRMS. Briefly, samples were analyzed on an Ultimate 3000
UHPLC with a Waters Xbridge C18 (2.1 x 150 mm, 3.5 µm particle size) with a two
solvent system where solvent A was 0.2 mM ammonium fluoride in water, and solvent B
was methanol. HRMS analysis was conducted on a Thermo Q Exactive Plus coupled to
an Ultimate 3000 UHPLC interfaced with a heated electrospray ionization (HESI-II)
source.

6-4: Results

Clinical characteristics:
Clinical characteristics for 9 of the 23 women could not be found at the time of this
analysis. Sample numbers are highlighted in grey for women with missing data (Tables
6.1 and 6.2). Clinical information for the remaining 14 women reflects patient
characteristics at time of entry into the cohort study. Age ranged from 23 – 73 at first
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Table 6.1. Age and receptor status of 23 WABC women

Subj ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Age*

ER

%
PR
%
Receptor status

Her2

60
23
58
49
65

+

70

+

15

+

+
+

100

+
+
+

100

+
-

49
46

+

+

-

34

+

+

-

73
45

+
+

99
40

+
+

6
95

+
+

44

+

75

+

75

-

49
48
39

+
+
+

80
100

+
+

80
90

+
-

80

1-4

*Age at first breast cancer diagnosis. In grey: clinical information missing
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Table 6.2. Rx, tumor pathology and local vs. distant recurrence in 23 WABC women
Prior
chemo

Prior Endo
Tx (#)

Stage

no AI, navelbine

no

2

1

moderately
differentiated

ductal

4

prior ana, current
lupron

yes

1

2A

not reported

ductal

5

ana

no

1

2

6

prior exe, current
ana

yes

1

2A

7

ana

yes

1

3A

8

yes

3

2B

10
11
12
13

ana
prior ana and let,
no current AI
let
let
let
ana

14

Subj ID

AI on entry

1
2

let
ana

3

9

no

4

not reported

3

1

exe

no

2

1

15

let

yes

2

3B

16
17
18
19
20

ana
ana
let
let
let
no current AI, fulv
+ zometa
prior exe, current
avastin
ana

yes

2

2B

no

2

1

yes

2

3C

yes

2

2

22
23
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well
differentiated
poorly
differentiated
poorly
differentiated
moderately
differentiated
not reported

no

21

Grade

Histology Relapse

distant

ductal

distant

mixed

distant

ductal

distant

mixed

distant

ductal
lobular

distant

ductal

distant

lobular

distant

not reported

lobular

distant

not reported
moderately
differentiated
moderately
differentiated

ductal

distant

ductal

distant

ductal

distant

moderately
differentiated
moderately
differentiated

breast cancer diagnosis (Table 6.1). ER status was positive for 11 women, negative for
one and not reported for two. PR status was positive for 11 women, negative for one and
not reported for two. 5/14 women were HER2 positive, 7/14 were HER2 negative and
HER2 status was not reported for two women (Table 6.1). AI treatment status was
available for all 23 women: 9 women were taking anastrozole at time of entry into the
study, 8 were taking letrozole, one was taking exemestane and for 5 women no AI was
reported at time of entry into the study (Table 6.2). Two of those women were on
chemotherapy (Navalbine or Avastin), two were taking endocrine targeted therapies
(Lupron or Fulvestrant + Zometa) and one discontinued AI due to bone loss (Table 6.2).
8/14 women had chemotherapy prior to entry into the cohort, and 6 had no prior
chemotherapy. 13/14 women had prior endocrine therapy, one did not, and among the
women with prior endocrine therapy the number of different drugs taken ranged from 13. Tumor stage reported ranged from stage I to stage IV. Tumor grade was not reported in
5 women, and was reported to be well-differentiated in one woman, moderatelydifferentiated in 6 women and poorly differentiated in 2 women (Table 6.2). 9 women
had ductal carcinoma, 3 had lobular carcinoma and 2 had mixed histology. 12/14 women
had distant recurrence, and for two women it was not reported (Table 6.2).

Total serum estrogen levels in 23 WABC women:
Total serum estrogens were quantified from 23 women in the WABC cohort (Figure
6.1). For many estrogen metabolites (EM) levels detected were below the lower limit of
quantification of the assay (BLQ). The mean is reported in two ways: a mean of levels
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Figure 6.1. Total estrogen levels present in serum of 23 WABC women. (A) Total estrone
extracted from 100 µl human serum after enzymatic hydrolysis and analyzed as a PS-conjugate
by LC-HRMS. (B) Total estrogen metabolites extracted from 100 µl human serum after
enzymatic hydrolysis and analyzed as PS-conjugates by LC-HRMS. BLQ = below limit of
quantification, NC = not calculated
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0

E1

Figure 6.2. Unconjugated estrone levels present in serum of 23 WABC women
Unconjugated estrone was extracted from 100 µl human serum and analyzed as a
GP-conjugate by LC-HRMS. BLQ = below limit of quantification
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detected and an adjusted mean to reflect the BLQ values found in a majority of women
for certain metabolites. For the adjusted mean, BLQ values were included as equal to the
lower limit of quantification of the assay (LLOQ; 0.5 pg/mL) rather than as zero. This
adjustment was made for total estrone, estradiol, estriol and 2-methoxy-estradiol,which
all had a LLOQ of 0.5 pg/mL. No adjustment was made for 2-hydroxy-estradiol as the
LLOQ was 5 pg/mL, and only a mean of values detected is reported in Figure 6.1. Total
serum estrone (unconjugated + glucuronide and sulfate conjugates) had a minimum level
of BLQ, a maximum of 610 pg/mL and a mean level of 127.9 pg/mL (adjusted mean 71.2
pg/mL) (Figure 6.1). Total estradiol was detected in two women, at 36.5 and 52.2 pg/mL
respectively. Total estriol was detected in 6 women with a minimum of BLQ, a maximum
level of 31.4 pg/mL and a mean level of 20.5 pg/mL (adjusted mean 5.7 pg/mL) (Figure
6.1). Total 2-methoxy-estradiol was detected in five women, with a minimum of BLQ, a
maximum of 13 pg/mL and a mean level of 11 pg/mL (adjusted mean 2.8 pg/mL). Total
2-hydroxy-estradiol was detected in four women, with a minimum of BLQ, a maximum
of 30.3 pg/mL and a mean level among levels detected of 23.3 pg/mL (Figure 6.1).

Unconjugated serum estrone in 23 WABC women:
Unconjugated serum estrone was analyzed using the keto-steroid GP method [173] and
was found to be detectable in 15/23 women (Figure 6.2). The minimum level was BLQ,
the maximum level was 79 pg/mL and the mean level was 24.1 pg/mL (adjusted mean
16.1 pg/mL). The LLOQ for quantifying estrone as a GP conjugate was 1 pg/mL and this
value was used to calculate the adjusted mean (Figure 6.2).
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D
A

T

Figure 6.3. Unconjugated testosterone and ∆4-androstenedione levels present in serum of 23
WABC women. Unconjugated T and 4-AD were extracted from 100 µl human serum and
analyzed as GP-conjugates by LC-HRMS. BLQ = below limit of quantification
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D
H
EA

-S

EA

A.

Figure 6.4. Endogenous levels of DHEA and DHEA-S quantified from serum of 23 WABC
women. A: Unconjugated DHEA extracted from 100 µl human serum and analyzed as a GPconjugate by LC-HRMS. B: DHEA-S analyzed from 10 µl human serum as intact steroid
conjugate by LC-HRMS
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Unconjugated serum androgen levels in 23 WABC women:
Androgen levels were quantifiable in all serum samples analyzed from a starting volume
of 100 µl, except for one patient who had no detectable testosterone (Figure 6.3).
Testosterone analyzed as a GP-conjugate by LC-HRMS had a mean level of BLQ (n=1) a
maximum level of 2.8 nM and a mean level of 1.1 nM (Figure 6.3). 4-androstenedione
was quantified at a mean level of 1.45 nM (range 0.03 – 4.23 nM) (Figure 6.3). Serum
DHEA had a much wider range with a mean level of 8.09 and a range of 0.33 – 24.93 nM
(Figure 6.4A).

DHEA-S in 23 WABC women:
DHEA-S was analyzed as an intact sulfate conjugate from a starting volume of 10 µl
human serum. This steroid also exhibited a wide range, with a mean level detected of
2.64 µM, and a range of 0.03 – 7.30 µM (Figure 6.4B).

Comprehensive serum measurements:
Table 6.3 presents the comprehensive serum measurements of unconjugated androgens
and E1 quantified as GP-conjugates, total EM quantified as PS-conjugates and a
measurement of intact DHEA-S. The maximum level quantified for each steroid analyzed
is highlighted in red text, and minimum, maximum, mean and adjusted mean when
calculated are reported.
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Table 6.3. Serum androgen and estrogen levels in 23 WABC women
Sample
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Min
Max
Mean
Adjusted
Mean

DHEA
T (nM) AD (nM) (nM)
2.71
1.91
11.03
0.36
1.22
9.79
0.48
0.69
1.47
0.43
3.00
21.04
0.25
1.16
6.79
2.80
0.82
2.89
2.95
2.06
7.69
0.19
1.19
2.15
0.63
1.67
16.11
0.68
0.90
3.99
0.49
1.46
10.48
0.44
1.03
5.20
0.30
0.98
5.17
6.08
1.30
5.81
0.89
0.98
2.68
0.53
1.38
14.22
0.08
0.03
0.76
1.17
2.26
12.53
0.89
2.41
9.64
0.19
1.57
4.12
4.23
24.93
1.62
BLQ
0.03
0.33
0.28
0.97
7.33
BLQ
0.03
0.33
2.80
4.23
24.93
1.11
1.45
8.09
NC

NC

NC

Total
Total
DHEA-S Free E1 Total E1 Total E2 Total E3 2M-E1 2Hy-E1
(µM) (pg/mL) (pg/mL) (pg/mL) (pg/mL) (pg/mL) (pg/mL)
3.37
5.29
12.9
30.3
0.17
32.9
82.6
14.8
4.82
17.9
166.3
19.2
8.6
23.3
2.76
0.66
79.0
167.6
31.4
9.6
1.86
21.5
0.52
3.5
12.9
6.71
41.0
293.8
13.3
12.6
30.3
1.00
5.02
9.7
52.2
11.2
14.4
0.90
32.8
166.3
2.48
27.8
2.56
15.7
0.53
27.4
47.3
18.3
7.30
1.6
20.1
0.70
12.9
2.87
2.20
13.4
1.77
4.45
62.7
610.3
36.5
26.0
13.0
25.1
0.03
10.5
2.67
4.0
0.03
BLQ
BLQ
BLQ
BLQ
BLQ
BLQ
7.30
79.0
610.3
52.2
31.4
13.0
30.3
2.53
24.1
127.9
44.4
20.5
11.0
23.3
NC

16.1
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Figure 6.5. Conjugated and unconjugated serum estrone quantified from 23 WABC women and
grouped by drug. (A) Total serum estrone grouped by drug; (B) Unconjugated serum estrone
grouped by drug.
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Serum estrone grouped by drug:
Total and unconjugated serum estrone measurements in the 23 women included in this
study were grouped by drug (Figure 6.5). Total estrone was detected in 2 out of 8 women
taking letrozole, in 6 out of 9 women taking anastrozole, in the one patient taking
exemestane and in 4 out of 5 women not on AI. Unconjugated estrone was detected in 4
out of 8 women taking letrozole, in 6 out of 9 women taking anastrozole, and in all of the
women not on AI. Unconjugated estrone was not detected in the patient taking
exemestane. Figure 6.5 presents total and unconjugated serum estrone grouped by drug.
Frequency of detection is noted, as well as a mean of levels detected, and an adjusted
mean taking into account the number of women who had a level of serum estrone below
the limit of quantification.

6-5: Discussion
In this report, we have demonstrated comprehensive sex steroid measurements in
23 women from the WABC cohort who progressed to metastatic breast cancer. Five
women were not taking AI at time of entry into the cohort study due to breast cancer
progression on prior AI, and were being treated with chemotherapy or other endocrinetargeted therapies. One patient started letrozole after progression on anastrozole, but then
discontinued AI due to bone loss.
Among the women reported to be on AI at time of entry into the WABC cohort
study, a wide range of estrogen metabolites could be detected. Altogether, about half of
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the women who progressed on AI (n=18) had detectable levels of total or unconjugated
E1. There were two women with total serum estrone concentrations greater than 100
pg/mL, comparable to the high levels detected by GC-MS among some women taking
anastrozole who did not exhibit serum estrogen suppression at the onset of therapy [68].
Three women on AI had serum unconjugated estrone levels greater than 21.8 pg/mL, the
mean level reported in healthy post-menopausal women by LC-SRM/MS (subsequently
referred to in this section as LC-MS) [83].
Among 18 women reported to be taking AI at time of entry into the study, one
was taking exemestane and the rest were roughly split between letrozole and anastrozole
(Table 6.2). Total serum E1 and unconjugated serum E1 was detected more frequently in
women on anastrozole compared with women on letrozole, but among women taking
either drug there were some women who did not exhibit serum estrogen suppression
(Figure 6.5). While this is a small data set, it is an interesting first look at the variety of
serum estrogen and androgen levels present in women who progressed to metastatic
breast cancer while on AI therapy (n=18). Future directions include expansion to a casecontrol study to enable comparison of serum estrogen and androgen levels among women
who relapse vs. those who do not. It will also be possible to compare serum steroid
hormone profiles among the three-third generation AI among women who are currently
responding to adjuvant AI therapy.
The association of serum androgen levels with breast cancer risk and potentially
relapse have been explored, though recent studies have indicated that androgenglucuronides rather than unconjugated androgens may be a better predictor of breast
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cancer risk [81, 87, 214]. Serum 4-androstenedione (4-AD) measured in this group of
women was exactly in line with levels reported in healthy post-menopausal women. The
mean here was 1.45 nM, and the mean 4-AD level found in healthy women using LC-MS
methods was 1.33 nM, with a range of mean levels found in different studies of 1.24 –
1.54 nM [83]. Unconjugated testosterone had a mean level of 1.06 nM, which is higher
than the mean level reported by LC-MS of 0.6 nM (range 0.38 – 0.86). Serum DHEA in
this group of women was 8.09 nM, higher than the mean level reported in healthy women
of 6.21 nM, range 5.79 - 6.62. The greatest difference was found in the serum level of
DHEA-S, with a mean level of 2.64 µM, which is 95% higher than the overall mean
reported by LC-MS in healthy post-menopausal women of 1.35 µM (range 0.96 – 1.63
µM) [83]. It is possible that the LC-HRMS method used to quantify the intact DHEAsulfate conjugate may yield higher levels, due to not relying on enzymatic hydrolysis
prior to analysis which can potentially be incomplete. For DHEA-S and for all steroid
hormones analyzed, expansion to a nested-case control study to allow comparison in
steroid hormone profiles among relapsers vs. non-relapsers will be informative.
Despite the differences in methodology used to quantify DHEA-S (intact vs. after
hydrolysis) it is interesting to consider the high serum levels of DHEA-S found in this
group of 23 women who progressed to metastatic breast cancer. In a small study, serum
DHEA-S levels higher than 2.42 µM were associated with relapse in women on adjuvant
AI [89]. Again, the absolute levels are difficult to compare due to methodological
differences, but in a group of 19 women the mean DHEA-S among relapsers (n=12) was
4 µM compared with 0.67 µM in women with stable disease. In a large prospective
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cohort study, women with serum DHEA-S concentrations in the highest quartile were
found to have a significantly higher breast cancer risk than those in with concentrations in
lowest quartile (risk ratio 2.8 (1.1 – 7.4) [87]. The same study found stronger associations
between circulating DHEA and its metabolite 5-androstendiol and breast cancer risk, with
risk ratios of 4.0 (1.3 - 11.8) for DHEA and 3.0 (1.0 - 8.6) for Adiol. Within the WABC
cohort, comparing DHEA and DHEA-S levels among women who relapse vs. those with
stable disease will provide insight into the association between this hormone and risk of
relapse on adjuvant AI.
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CHAPTER 7: Conclusions and Future Directions

7-1: Conclusions
LC-MS/MS and LC-HRMS assays have been applied for highly sensitive
quantification of estrogens and androgens at levels relevant to post-menopausal women
and women on AI. The application of these methods was twofold: to understand
androgen metabolism and comparative potency of third-generation AI in in vitro models
of aromatase inhibitor therapy and resistance, and to conduct an exploratory clinical
analysis to quantify a comprehensive panel of serum estrogen and androgens in women
who progressed to metastatic breast cancer (n=23).

7-1A: Third-generation AI potency in vitro and in vivo
In vitro studies assessing biochemical potency of third-generation AI have
demonstrated differences in degree of estrogen suppression among commonly used AI, as
well as in models of AI responsive vs. resistant breast cancer (Chapter 4). An interesting
finding that came from this study is that LTEDAro, a MCF-7-derived model of acquired
resistance to AI demonstrated an enhanced catalytic activity of aromatase compared with
MCF-7Aro. For example, substantial levels of estrone could be quantified from culture
medium of LTEDAro cells after incubation with 5 nM 4-AD and anastrozole (168
pg/mL) vs. 74 pg/mL detected in MCF-7Aro cells grown under the same conditions. The
same experiment repeated with 1 µM letrozole demonstrated suppression of estrone
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formation to 4 pg/mL in both cell lines. First, this demonstrates the substantial difference
in potency between the two drugs, which has been observed in other pre-clinical [200]
studies and some small clinical studies [68, 193]. Second, it is interesting to consider in
light of the prevailing view in the field of the progression towards hormone-independence
in breast cancer. The transition to AI resistance has been described as a progression first
to a growth phase in which cells are hypersensitive to estradiol [233], followed by a later
growth phase where cells have become totally estrogen independent [54]. This model has
been proposed as a result of pre-clinical studies assessing cell signaling changes that
occur when ER+, aromatase-expressing cells are grown long-term in the total absence of
estrogens (LTED cell models) [54, 59, 234]. Since LTEDAro is a model of acquired
resistance to AI, does it matter that it has a higher capacity for local estrogen production?
The models described above assume complete and sustained estrogen suppression in the
presence of AI, but as found in this study and elsewhere [68, 194], it is questionable
whether that is the case for many women on AI. What are the resistance mechanisms that
can develop long-term when there is incomplete estrogen suppression vs. complete? Is
inadequate estrogen suppression itself a driver of tumor recurrence? It was demonstrated
that different resistance mechanisms emerge in LTED models after adaptation to growth
in trace levels of estradiol vs. the absence of estradiol [228] and CYP19A1 (aromatase)
gene amplification as well as increased aromatase activity was observed in AI-treated
women who progressed to metastatic breast cancer [67].
Application of LC-MS/MS or LC-HRMS methods can provide an accurate view
of variability of estrogen suppression in women taking AI both initially and in the
adjuvant setting. The exploratory analysis conducted within the WABC cohort study
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demonstrated the substantial levels of estrogens which were quantified from 10/18
women on adjuvant AI who progressed to metastatic disease. Expansion of this study to a
nested-case control study within the WABC cohort will allow comparison of serum
estrogen and androgen levels among women who relapse on adjuvant AI vs. those who
do not.

7-1B: DHEA-S action in breast cancer
Limited epidemiological evidence suggests an association of high circulating
DHEA-S levels with breast cancer risk, and possibly with breast cancer recurrence, but
the mechanisms of DHEA-S-mediated proliferation in breast cancer are not wellunderstood. DHEA-S can stimulate proliferation in MCF-7 cells through ER [97] and
now has been demonstrated to stimulate proliferation in MCF-7 variant cell lines which
were developed to model AI-responsive and AI-resistant breast cancer (MCF-7Aro and
LTEDAro, respectively). DHEA-S stimulated growth was inhibited by fulvestrant in a
dose-dependent manner, indicating an ER-dependent mechanism. The question of
whether DHEA-S requires metabolism to estrogens to exert a biological effect in breast
cancer remains unclarified. In this study, LC-HRMS analysis demonstrated formation of
estrogens from DHEA-S in MCF-7 only in the presence of aromatase. Moderate estrone
levels were formed in MCF-7Aro and LTEDAro from DHEA precursors as well as low
pM concentrations of estradiol in both cell lines. 4-androstenedione was detected
downstream of DHEA in parental MCF-7, but in the absence of aromatase no estrogens
were detected.
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The question of whether these estrogen levels are sufficient to explain the
significant growth response demonstrated in MCF-7 variant cell lines as well as the
parental MCF-7 cell line requires further study. It is possible, as tumors deprived of
estrogens can demonstrate both enhanced aromatase activity as well as hypersensitive
growth in the presence of estrogens. Alternately, the potential metabolism of DHEA or
DHEA-S to 5-androstenediol and subsequent direction action through ER is an intriguing
possibility which would represent DHEA-S stimulated growth at the site of the breast
tumor which is independent of aromatase activity [219].
Both DHEA and DHEA-S were found to have a wide biological range in WABC
women who progressed on AI, with mean levels reported were 30% and 95% higher than
levels reported in healthy post-menopausal women by LC-MS/MS ([83]and Chapter 6).
Expansion to a nested case-control study will shed light on whether there are differences
in levels of these hormones in women who relapse on adjuvant AI vs. those who do not.
Is there a level of DHEA-S among WABC women which would be predictive of relapse?
It was previously reported that serum DHEA-S levels higher than 2.32 µM were
associated with relapse in a small clinical study [89], and the mean level found in this
analysis was higher than that (2.64 µM).
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7-2: Future directions

7-1A: LC-MS to monitor AI therapy and response in breast cancer
Future directions for comprehensive serum steroid hormone measurements within
the WABC II cohort includes expansion to a nested case control study to compare serum
steroid hormone profiles between women who relapse and those who do not. Additional
studies of interest are relationship between circulating metabolites and symptom distress
on AI.
Expansion of the existing LC-HRMS assay to include monitoring of drug
metabolites in women on AI would allow for sensitive detection of estrone and estradiol
as well as AIs (parent drug or metabolites). The targeted / untargeted data acquisition
achieved by a hybrid quadrupole / orbitrap instrument means that the full scan data can
be mined for presence of AIs or their metabolites using accurate mass information.
Expanding the assay to a multiplexed, targeted assay that can monitor estrone, estradiol
as well as AI metabolites is also possible. Simultaneous monitoring of estrogens as well
as AI by LC-HRMS would be very useful in the adjuvant AI population as it would allow
for confirmation of drug compliance as well as potential investigation into differences in
drug metabolism seen among responders vs. non-responders.
More generally, applications of accurate MS-based assays to monitor androgens
and estrogens in post-menopausal women and women on AIs on a larger scale can help
define the baseline variability of steroid hormones in these populations and understand
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variability in AI response. There is a wide range of mechanisms of resistance to AI in
ER+ breast cancer, and a better understanding of the associations between suboptimal
estrogen suppression in women on AI and disease outcomes can provide important
mechanistic information regarding the development of resistance to AI in different
microenvironments. Including comprehensive androgen measurements can also shed
light on whether risk of relapse is related to levels of adrenal androgens in circulation.
Finally, the potential exists for personalized monitoring of AI therapy using LC-MS or
LC-HRMS techniques to better tailor therapy based on individual response.

7-1B: Understanding intracrine modulation in response to estrogen deprivation in
breast cancer: a role for AKR1C3 in metabolism and biological response to DHEAS in ER+ breast cancer?
In light of the experiments presented in Chapter 5 investigating DHEA and
DHEA-S metabolism in ER+ breast cancer cells +/- aromatase many questions remain
unanswered about the metabolism and biological action of DHEA and DHEA-S in breast
cancer. How does local modulation of steroid metabolizing enzymes such as steroid
sulfatase, 17β-HSD and AKR1C3 affect the metabolism and subsequent biological
function of DHEA or DHEA-S? Byrns et al. demonstrated that overexpression of
AKR1C3 in MCF-7 promotes a pro-estrogenic state, and a preferential conversion of
estrone to the more potent 17β-estradiol [44]. It was additionally demonstrated that
overexpression of AKR1C3 in prostate cancer cells (LNCaP) modulated metabolism of
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adrenal androgens to increase local production of testosterone, thus conferring resistance
to finasteride, which targets 5α-reductase to deprive prostate tumors of the potent AR
ligand dihydrotestosterone (DHT) [235]. The parallels to breast cancer are interesting as
specific inhibitors target the aromatase pathway, yet upregulation of other steroid
hormone metabolizing pathways such as steroid sulfatase, 17β-HSD enzymes or
AKR1C3 has the potential to increase local formation of ER ligands through pathways
other than aromatization [37, 41, 43, 44].
AKR1C3 catalyzes the conversion of estrone to 17β-estradiol, and also of DHEA
to 5-androstenediol, an androgen which can directly bind ER and stimulate cell
proliferation in breast cancer cells [218, 219]. Future investigations of DHEA metabolism
in MCF-7 cells overexpressing AKR1C3 would be extremely informative in order to
better understand the capacity for AKR1C3 to modulate the biological response of breast
cancer cells to DHEA and DHEA-S. Yi Jin et al. demonstrated the capacity for AKR1C3
to directly catalyze conversion of conjugated steroids without the necessity for prior
deconjugation by steroid sulfatase [236]. This also raises the question of whether
AKR1C3 would preferentially catalyze reduction of DHEA-S at physiological
concentrations over unconjugated DHEA in breast cancer, as DHEA-S is present in
circulation at levels 1000x greater than the unconjugated form.
The capacity for breast tumors to modulate adrenal androgen metabolism to
enhance production of ER ligands without the involvement of the aromatase pathway is
an important potential mechanism of resistance to AI therapy in breast cancer. As a final
note, a small clinical study was previously cited which discussed circulating DHEA-S
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levels in 19 women being treated with AI [89]. Among the 12 women who relapsed on
AI, 11 of them had substantially elevated DHEA-S concentrations compared with
controls. These 11 women were subsequently treated with aminoglutethimide (AG)
(n=11) or adrenalectomy (n=1). 8 women treated with AG as well as the patient treated
with adrenalectomy experienced tumor regression. The authors proposed that
adrenalectomy should continue to be considered as a treatment for women at risk of
relapse due to high circulating DHEA-S levels. The rational development of specific
inhibitors to aromatase, and their subsequent outstanding clinical success demonstrated
that endocrine therapy of ER+ cancer has come a long way from adrenalectomy. But as
an anecdote, the clinical response seen in these 9 women as a result of targeting adrenal
function in late-stage breast cancer after progression on AI demonstrates that there is still
more to learn.
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